The study focus the lecturer posted comes first, then criteria, scores and classifications: one table per set from the slides, each with a labeled memory aid. Respiratory Block Exam II, condensed from the Exam 7 study guide. Lectures covered: 39 (phases of sleep), 40 (obstructive sleep apnea and obesity hypoventilation syndrome), 41 (inflammatory lung diseases), 42 (pulmonary vascular disease), 43 (pulmonary nodules and neoplasms), 44 (pleural disorders), 45 (acid-base part II). Each lecture opens with a gold card of what its lecturer stressed (starred; from the recording once it is in); every fact still comes from the slides.
| Things to Know (slide 49) | The answer, from the slides |
|---|---|
| The criteria for screening an asymptomatic and at-risk patient | No symptoms, no known nodule; 55–80; at least 30 pack-years; smokes now or quit within 15 years → annual low-dose chest CT (computed tomography) |
| A benign nodule’s appearance | Well-defined borders, fat (hamartoma), calcification (diffuse, central, popcorn = hamartoma, concentric), next to a fissure; under 6 mm and not high risk |
| What makes you concerned for a malignant nodule | Over 6 mm; upper lobe or hilar; spiculated (spiky border); more than 3; enlarging; contrast-enhancing; cavitated or nonsolid; high-risk patient; ground-glass or eccentric calcification |
| Staging by size, nodes and metastasis (TNM), and how it changes treatment | N2 or N3 = stage 3; M1 = stage 4. Non-small cell: stages 1–2 surgical resection, stage 4 chemotherapy; chemotherapy and radiation are adjuncts (non-small cell responds poorly) |
| Which cancers are peripheral or central | Central: small cell and squamous cell. Peripheral: adenocarcinoma and large cell |
| Recognize squamous cell among the non-small cell cancers | Strongest smoking link; central, from a bronchus; cough, wheezing, hemoptysis; cavitation; caught by sputum cytology; hypercalcemia |
| Recognize small cell lung carcinoma (SCLC) | Oat cell; central; over 70% metastatic before detection; neuroendocrine paraneoplastic syndromes (SIADH, syndrome of inappropriate antidiuretic hormone); no nucleoli, high nuclear-to-cytoplasm ratio, crushed at biopsy |
| Which cancer benefits most from radiotherapy | Small cell: responds better to chemotherapy and radiation than the non-small cell types; best in limited stage; prophylactic cranial irradiation |
| Paraneoplastic signs (“i.e. small cell”) | SIADH: low sodium and osmolality → confusion, seizures, ataxia, no edema; hypercalcemia (squamous); Lambert-Eaton leg weakness; carcinoid syndrome (bronchial carcinoid) |
Screen, Smooth, Spiky, Stage, Site, Squamous, Small, Shoot (radiation), Syndromes: nine S’s for nine bullets.
Screen screening criteriaSmooth benign appearanceSpiky concerning nodule (spiculated)Stage TNM and its treatmentSite central or peripheralSquamous recognize squamous cellSmall recognize small cellShoot radiotherapy benefits small cell mostSyndromes paraneoplastic signs
Where it breaks: “Smooth” stands for all the benign signs (fat, calcification, fissure), not only smooth borders.
| Wave | Frequency (cycles/second) | Where and when |
|---|---|---|
| Beta | Greater than 14 (as high as 80) | Parietal and frontal regions; asynchronous, low voltage; awake, alert, actively processing information |
| Alpha | 8–13, rhythmical | Healthy adults awake, quiet and resting; most intense occipital; disappear in deep sleep; replaced by beta when attention is directed to a task |
| Theta | 4–7 | Parietal and temporal regions in children; emotional stress in some adults (disappointment, frustration); degenerative brain disorders |
| Delta | Less than 3.5 | Voltage 2–4 times other waves; strictly cortical; very deep sleep, infancy, serious organic brain disease, cortex cut off from the thalamus |
Fastest to slowest the waves spell BAT-D: Busy, At rest, Tired, Deep.
B Beta: busy, alert, actively processing (>14)A Alpha: awake but at rest, quiet (8–13)T Theta: tired (light sleep), children, stress, brain disorders (4–7)D Delta: deep sleep, infancy, organic brain disease (<3.5)
Where it breaks: “Tired” covers only theta’s sleep use; its children, stress and brain-disorder settings must be learned separately.
| Stage | What happens | EEG |
|---|---|---|
| Awake, eyes open | Alert and active | Beta |
| Awake, eyes closed | Decreased alertness, relaxation | Alpha |
| N1 | Transition from wakefulness; drowsy; light sleep | Theta |
| N2 | Deeper sleep; heart rate and temperature fall; longest stage by total duration | Theta; sleep spindles (12–14 Hz bursts); K complexes (negative sharp wave then positive component) |
| N3 (deep, slow-wave) | Deepest non-REM stage; harder to arouse; growth and repair; decreases with age | Delta |
| REM (stage R) | Dream state; rapid, irregular eye movements; atonia except eyes and diaphragm; sawtooth waves | Beta (like awake, with atonia) |
| Slide 27 and the slide 29 picture use FOUR non-REM stages and put spindles in stage 1; the slide 28 table (above) uses three and puts spindles in N2. | ||
BATTeD, then Back: down the night the waves go Beta, Alpha, Theta, Theta, Delta, and REM goes Back to beta.
B Eyes open: betaA Eyes closed: alphaT N1: thetaT N2: theta (+ spindles, K complexes)D N3: deltaBack REM: back to beta, with atonia
Where it breaks: The vowel “e” in BATTeD stands for nothing.
| Measure | Value |
|---|---|
| Average sleep | 8 hours |
| Cycles per night | 4–5 |
| Length of one cycle | 90–120 minutes |
| REM share of a young adult’s sleep | About 25% |
| REM episodes | Recur about every 90 minutes; each lasts 5–30 minutes |
| Non-REM fall in blood pressure, heart rate, breathing, metabolic rate | 10–30% |
| REM rise in brain metabolism | Up to 20% |
8 hours, 4–5 laps of 90: a quarter of it dreaming.
8 hours of sleep on average4–5 cycles90 minutes: cycle length starts at 90 (to 120) and REM recurs every 90A quarter REM is about 25% of a young adult’s sleep
Where it breaks: Leaves out the 5–30 minute REM episode, the 10–30% non-REM fall and the 20% REM rise: learn those from the table.
| Term | Airflow | Respiratory effort |
|---|---|---|
| Apnea | Decrease of 90% or more (thermistor), lasting at least 10 seconds | — |
| Hypopnea | Slowed, shallow, restricted breathing in episodes of 10 seconds or longer | — |
| Obstructive apnea | None | Continued |
| Central apnea | None | None |
| Mixed apnea | None | Absent early in the event, resumes later |
Ninety for Ten; then ask the chest: Obstructive keeps On trying, Central has Ceased, Mixed Makes up its mind late.
90 / 10 apnea: airflow down 90% or more for 10 seconds or moreO Obstructive: effort ongoingC Central: effort ceasedM Mixed: effort missing, then made
Where it breaks: Hypopnea has no percentage on the slide, only the 10-second episodes.
| Item | What the slide says |
|---|---|
| Criterion 1 | 5 or more predominantly obstructive respiratory events per hour of sleep plus one symptom: sleepiness, fatigue, insomnia or impaired sleep-related quality of life; waking with breath holding, gasping or choking; habitual snoring or breathing interruptions seen by a bed partner |
| Criterion 2 | 15 or more predominantly obstructive respiratory events (no symptom needed; the slide gives no time unit here) |
| And | Symptoms not explained by another medical or sleep condition, medications or substance use |
| Apnea-hypopnea index | (apneas + hypopneas) ÷ total sleep time in hours |
| Respiratory disturbance index | (apneas + hypopneas + respiratory effort-related arousals) ÷ total sleep time in hours |
| Mild, moderate and severe index bands appear only in the speaker notes, not on a slide. | |
Five needs a friend; fifteen stands alone.
5 5 or more events per hour needs one symptom15 15 or more events is enough on its own (no time unit on the slide)
Where it breaks: Both still need the symptoms to be unexplained by another condition, drug or substance.
| Letter | Yes if (1 point each) |
|---|---|
| Snoring | Snores loudly (through closed doors, or the bed partner elbows you) |
| Tired | Often tired, fatigued or sleepy in the daytime |
| Observed | Someone observed you stop breathing, or choking or gasping, during sleep |
| Pressure | Have, or being treated for, high blood pressure |
| BMI | Body mass index more than 35 kg/m² |
| Age | Older than 50 |
| Neck | Neck (shirt collar) 16 inches / 40 cm or larger |
| Gender | Male |
| RISK (general population) | |
| Low | Yes to 0–2 |
| Intermediate | Yes to 3–4 |
| High | Yes to 5–8, or 2 or more of the 4 STOP questions plus male gender, or plus body mass index over 35, or plus neck 16 inches / 40 cm |
| Not for routine community screening or asymptomatic patients; used preoperatively; the highest sensitivity of the questionnaires (slide 16). The risk-factor neck size on slides 6–7 is 17 inches (men) / 16 (women). | |
The name is the mnemonic: STOP (four symptoms) and Bang (four facts).
S Snoring loudlyT Tired in the daytimeO Observed apneas, choking or gaspingP Pressure: high blood pressureB BMI over 35A Age over 50N Neck 16 inches / 40 cm or moreG Gender male
Where it breaks: Risk bands 0–2 / 3–4 / 5–8 and the 2-STOP-plus rules are not in the name: learn them from the table.
| Use a polysomnogram, NOT a home kit, with: |
|---|
| Stroke |
| Neuromuscular weakness |
| Long-term opioid use |
| Significant cardiopulmonary disease |
| Awake hypoventilation or hypoxemia |
| Severe insomnia |
| Concern for a non-obstructive sleep disorder |
| Home kits assess only obstructive sleep apnea and will not always diagnose mild disease (helpful for moderate to severe). Central sleep apnea: home testing is not sufficient (slide 26). |
A SNOCHIN (a snoring chin) with any of these sleeps in the lab.
S StrokeN Neuromuscular weaknessO Opioids, long termC Cardiopulmonary diseaseH Hypoventilation or hypoxemia while awakeI Insomnia, severeN Non-obstructive sleep disorder suspected
Where it breaks: Made up here; the slide lists them in a different order.
| Step | What the slides say |
|---|---|
| SCREEN an obese patient (with or without obstructive sleep apnea) who has | |
| Oxygen saturation | Unexplained awake room-air saturation 94% or less, or overnight lowest below 80% |
| Symptoms and signs | Unexplained dyspnea on exertion; pulmonary hypertension or right-sided heart failure (elevated jugular venous pressure, hepatomegaly, pedal edema); facial plethora (facial swelling, puffiness) |
| Labs | Raised bicarbonate; when suspicion is low to moderate, serum bicarbonate over 27 → arterial blood gas |
| DIAGNOSE by exclusion: all three | |
| 1 | Obesity: body mass index over 30 |
| 2 | Awake alveolar hypoventilation: arterial carbon dioxide pressure over 45 mm Hg |
| 3 | Alternative causes of hypercapnia and hypoventilation excluded |
| Gold standard | Polysomnography with continuous nocturnal carbon dioxide monitoring |
| TREAT | |
| Approach | Multidisciplinary |
| First line | Weight loss program + positive airway pressure: with obstructive sleep apnea → CPAP; with sleep-related hypoventilation → BiPAP |
| Lifestyle | Diet changes, exercise, behavioral modifications |
| Second line | Tracheostomy with nocturnal ventilation (very effective); bariatric surgery; medications only after diet and exercise fail |
Screen at 94-80-27; diagnose at 30-45-zero.
94 awake saturation 94% or less80 overnight nadir below 80%27 bicarbonate over 27 means get a blood gas30 body mass index over 3045 arterial carbon dioxide over 45 mm Hgzero zero other causes (diagnosis of exclusion)
Where it breaks: The screening signs without numbers (dyspnea, right heart failure, facial plethora) and the treatment rows (multidisciplinary, first line, lifestyle, second line) are not in the numbers.
| Outcome | Risk |
|---|---|
| Driving accidents | 2.5 times |
| Sudden cardiac death AT NIGHT | 3–6 times |
| Hypertension | 3 times |
| Nonalcoholic fatty liver disease (prevalence) | 2–3 times |
| Gastroesophageal or laryngopharyngeal reflux | 75–100% of patients; improves with CPAP |
Count up the night: 2.5 crashes, 2 to 3 livers, 3 pressures, 3 to 6 hearts stop, and nearly all reflux.
2.5 driving accidents2–3 fatty liver3 hypertension3–6 sudden cardiac death at night75–100% reflux
Where it breaks: Heart failure mortality, pulmonary hypertension, stroke, arrhythmias and ischemic heart disease carry no number on the slides.
| Onset | Time course | Typical of |
|---|---|---|
| Acute | Days to weeks | Allergy |
| Subacute | Weeks to months | Any, but most common with sarcoidosis and drug-induced disease |
| Chronic | Months to years | Most interstitial lung diseases: idiopathic pulmonary fibrosis, sarcoidosis, pneumoconiosis, connective tissue disease |
| Episodic | Less common | Hypersensitivity pneumonitis |
All Sorts Come Eventually: Allergy fast, Sarcoid and drugs Sub, Chronic for most, hypersensitivity comes and goes (Episodic).
A Acute (days to weeks): allergyS Subacute (weeks to months): sarcoidosis, drug-inducedC Chronic (months to years): most, including idiopathic pulmonary fibrosis, sarcoidosis, pneumoconiosis, connective tissue diseaseE Episodic: hypersensitivity pneumonitis
Where it breaks: Sarcoidosis sits in both the subacute and the chronic rows on the slide.
| Finding | Meaning |
|---|---|
| RETICULAR (curvilinear) OPACITIES | |
| Fine (ground glass) | Early finding |
| Medium (honeycombing) | Late finding |
| Coarse | Cystic spaces |
| OTHER PATTERNS | |
| Nodular | Nodules |
| Reticulonodular | Reticular shadows overlapping, or with nodules (sarcoid) |
| Hilar and mediastinal lymphadenopathy | Sarcoidosis, silicosis |
| RESTRICTIVE PATTERN | |
| Forced expiratory volume in 1 second ÷ forced vital capacity | Normal or increased |
| Total lung capacity and forced vital capacity | Decreased |
Ground glass Goes first, Honeycomb Hangs on late; in restriction the Ratio is Retained while the volumes are Reduced.
G ground glass = fine, earlyH honeycombing = medium, lateCoarse cystic spacesRatio retained normal or increased ratioVolumes reduced total lung capacity and forced vital capacity decreased
Where it breaks: The other patterns (nodular, reticulonodular, hilar adenopathy in sarcoidosis and silicosis) have no letter.
| Test | Points to |
|---|---|
| Sedimentation rate increased | Active sarcoidosis |
| High antinuclear antibody | Collagen vascular disease |
| c-ANCA (cytoplasmic antineutrophil cytoplasmic antibody) | Granulomatosis with polyangiitis |
| Anti-glomerular and anti-alveolar basement membrane antibodies | Goodpasture syndrome (glomerulonephritis + diffuse pulmonary hemorrhage, young adults) |
| Elevated angiotensin-converting enzyme | Sarcoidosis; the slide also writes “hypersensitivity silicosis” |
| Eosinophilia | Eosinophilic pneumonia, sarcoidosis, drug-induced |
| Slide 44: the angiotensin-converting enzyme is elevated in 40–80% of sarcoidosis patients. | |
Sarcoid has the ACE (angiotensin-converting enzyme) and the Sed rate; GPA (granulomatosis with polyangiitis) is C-ANCA; Goodpasture hits the Basement (lung and kidney); ANA means Autoimmune.
ACE + Sed sarcoidosis (active)C-ANCA granulomatosis with polyangiitisBasement anti-basement membrane: GoodpastureANA collagen vascular (autoimmune) disease
Where it breaks: Eosinophilia (three causes) and the slide’s “hypersensitivity silicosis” beside the enzyme are not in the hook.
| # | In a patient over 65 (all four = 90% confidence, no surgical lung biopsy) |
|---|---|
| 1 | Idiopathic disease by history, with inspiratory crackles on examination |
| 2 | Restrictive physiology on pulmonary function testing |
| 3 | Radiographic evidence of progressive fibrosis over several years |
| 4 | Diffuse, patchy fibrosis with pleural-based honeycombing on high-resolution CT |
| Corticosteroids may be used in cryptogenic organizing pneumonia, lymphoid interstitial pneumonia and nonspecific interstitial pneumonia (slide 38); for idiopathic pulmonary fibrosis nothing has improved survival and smoking cessation is critical (slide 37). | |
Over 65 and CRPH (crackles, restriction, progression, honeycomb): skip the biopsy.
C Crackles (inspiratory) in idiopathic diseaseR Restrictive physiologyP Progressive fibrosis over years on filmsH Honeycombing, pleural-based, on high-resolution CT
Where it breaks: The age (over 65) is outside the four letters.
| Stage | Chest film |
|---|---|
| I | Bilateral hilar adenopathy alone |
| II | Hilar adenopathy and parenchymal involvement |
| III | Parenchymal involvement alone (diffuse reticular infiltrates) |
| IV | Advanced fibrosis: honeycombing, hilar retraction, bullae, cysts, emphysema |
| Best prognosis with hilar adenopathy alone; parenchymal involvement is worse; 20% with lung involvement get irreversible impairment (slide 48). Biopsy whenever lymphoma or another diagnosis is possible (slide 45). | |
Nodes, Nodes + lung, Lung, Scar.
I nodes (hilar adenopathy) aloneII nodes + lungIII lung aloneIV scar (fibrosis, honeycombing)
| Indication (slide 47) | Organ |
|---|---|
| Hypercalcemia | Calcium |
| Cardiac involvement | Heart |
| Iritis, uveitis | Eyes |
| Granulomatous hepatitis | Liver |
| Progressive pulmonary lesions | Lungs (progressive) |
| Cutaneous lesions other than erythema nodosum | Skin |
| Arthritis | Joints |
| Central nervous system involvement | Brain |
| Disabling constitutional symptoms | Constitution |
| About 90% respond to corticosteroids. Intolerant or refractory: methotrexate, azathioprine or infliximab (slide 46). | |
Calcium HELPS JB’s Constitution.
C Calcium: hypercalcemiaH Heart: cardiac involvementE Eyes: iritis, uveitisL Liver: granulomatous hepatitisP Progressive pulmonary lesionsS Skin lesions other than erythema nodosumJ Joints: arthritisB Brain: central nervous system involvementConstitution disabling constitutional symptoms
Where it breaks: Erythema nodosum alone is the skin exception: it is NOT an indication.
| Coal workers’ pneumoconiosis | Asbestosis | Silicosis | |
|---|---|---|---|
| Exposure | Coal dust | Insulation, demolition, shipyards, construction (10–20 years; seen about 15 years later) | Mining, sandblasting, quarry, stone work (crystalline silica) |
| Where | Upper lung fields | Bases | Upper lobes (lighter dust) |
| Hallmark | Coal macules 2–5 mm | Pleural plaques (most common film finding); ferruginous bodies; CT preferred | Silicotic nodules 1–10 mm; eggshell calcification of hilar nodes; milky lavage |
| Function | Restrictive, reduced diffusing capacity | Reduced vital capacity and total lung capacity | Reduced forced vital capacity and forced expiratory volume |
| Watch for | Progressive massive fibrosis | Lung cancer (smokers) and mesothelioma (10% lifetime) | Tuberculosis (skin test + current chest film), progressive massive fibrosis, scleroderma |
| Treatment | Supportive: oxygen, vaccines, rehabilitation, stop smoking; transplant | Supportive: fibers cannot be removed | Supportive; stop smoking |
Coal and silica float UP, asbestos sinks DOWN; asbestos Plants Plaques and Mesothelioma, silica brings Tuberculosis and Eggshells.
Up coal (upper fields) and silica (upper lobes)Down asbestos (bases)Plaques + mesothelioma asbestosTuberculosis + eggshells silica
Where it breaks: The hook leaves out the coal macules (2–5 mm), the silicotic nodules, progressive massive fibrosis (coal and silica), lung cancer, scleroderma, and the function and treatment rows.
| Type | Timing | Signs and symptoms |
|---|---|---|
| Acute | Within 9 hours of exposure | Flu-like illness (fever, chills, muscle or joint pain, headache), rales, cough |
| Subacute | Multiple exposures (15%) | Rales, cough, chronic bronchitis, shortness of breath, anorexia or weight loss |
| Chronic | Multiple exposures (5%) | Cough, chronic bronchitis, shortness of breath, anorexia or weight loss, fatigue, lung fibrosis, clubbing |
| Slide 66: symptoms, with nausea 4–8 hours after exposure; slide 67: acute disease within 9 hours of exposure. | ||
Acute is the Flu; chronic adds the three Fs: Fatigue, Fibrosis, Fingers (clubbing).
Flu acute: flu-like illness, rales, coughFatigue chronic onlyFibrosis chronic onlyFingers clubbing, chronic only
Where it breaks: Subacute has no letter: it sits between (rales, cough, bronchitis, dyspnea, weight loss).
| Item | What the picture says |
|---|---|
| CORE DIAGNOSTIC CRITERIA | |
| Acute onset | Develops within 7 days of a known clinical insult |
| Bilateral opacities | New opacities not explained by effusion, atelectasis or nodules |
| Non-cardiogenic | Failure not fully explained by heart failure or fluid overload |
| Oxygenation | Arterial oxygen pressure ÷ fraction of inspired oxygen under 300 mm Hg (or saturation ÷ fraction under 315) |
| SEVERITY (arterial oxygen pressure ÷ fraction of inspired oxygen) | |
| Mild | 200–300 mm Hg |
| Moderate | 100–200 mm Hg |
| Severe | Under 100 mm Hg |
| Example: arterial oxygen 60 mm Hg on 50% oxygen (0.5) = 120, moderate. The management picture (slide 74) gives plateau pressure “under 50 cm H2O”, which differs from current guidelines (see the guide note); no question keys the number. | |
A-R-D-S: Acute, Radiograph, Doesn’t come from the heart, Short of oxygen; then grade by 3-2-1 hundred.
A Acute: within 7 days of an insultR Radiograph: bilateral opacities not from effusion, atelectasis, nodulesD Doesn’t come from the heart: not fully explained by heart failure or fluid overloadS Short of oxygen: ratio under 3003-2-1 mild 200–300, moderate 100–200, severe under 100
| Acute cor pulmonale | Chronic cor pulmonale | |
|---|---|---|
| Primary etiology | Massive pulmonary embolism | COPD, ILD, PAH (chronic obstructive pulmonary disease, interstitial lung disease, pulmonary arterial hypertension) |
| Time course | Minutes to hours | Months to years |
| Right ventricular adaptation | Sudden dilation & dysfunction | Concentric hypertrophy followed by late dilation |
| Classic presentation | Severe sudden dyspnea, sweating, rapid pulse, pallor, syncope | Unproductive cough, progressive exertional dyspnea, “Blue Bloater” phenotype |
| Key hemodynamic threat | Decreased left ventricular filling & immediate cardiovascular collapse (shock) | Progressive volume overload, hypoxemia, and right heart failure |
| Slide 4: cor pulmonale = elevated mean pulmonary artery pressure with a NORMAL wedge pressure; left heart failure (Group 2) is not cor pulmonale. | ||
Acute Dilates, Chronic Concentrates: a sudden clot gives the thin right ventricle no time to grow, so it balloons; years of lung disease let it thicken first.
Acute massive embolism, minutes to hours, sudden dilation, shockChronic COPD, ILD, PAH; months to years; concentric hypertrophy, late dilation
Where it breaks: Chronic disease still ends in dilation (“late dilation”).
| Step / test | What it does | Result |
|---|---|---|
| COR PULMONALE / PULMONARY HYPERTENSION PATHWAY (slide 12) | ||
| 1. Chest X-ray & pulmonary function tests | Interstitial markings or hyperinflation vs clear fields; obstructive vs restrictive | Lung disease → Group 3 |
| 2. V/Q (ventilation/perfusion) scan or CT pulmonary angiography | Exclude segmental defects (chronic thromboembolic disease, embolism) | Defects → Group 4 |
| 3. Right heart catheterization & echo | Confirm right ventricular strain, measure hemodynamics | Elevated mean pulmonary artery pressure, wedge ≤15 mmHg → Group 1 |
| SCREEN, DIFFERENTIATE, CONFIRM (slide 24) | ||
| Echocardiography | The most useful initial test: right ventricular size, TAPSE (tricuspid annular plane systolic excursion), pulmonary pressures; finds left-sided mimics | Screening |
| V/Q scan | Essential test to exclude CTEPH (chronic thromboembolic pulmonary hypertension); do not rely on CT angiography alone | High-probability mismatch → surgical pathway (thromboendarterectomy) |
| Right heart catheterization | “The mandatory gold standard”: mean pulmonary artery pressure, wedge pressure, pulmonary vascular resistance | Confirms pre-capillary pulmonary hypertension |
Lungs, then Clots, then the Catheter: each step takes one group off the table, and what is left is Group 1.
Lungs chest film + pulmonary function tests → Group 3Clots V/Q or CT pulmonary angiography → Group 4Catheter right heart catheterization + echo → Group 1 (wedge ≤15)
Where it breaks: Echo is the first test in practice (slide 24, screening) even though it sits in step 3 of slide 12.
| Group | Mechanism | Examples |
|---|---|---|
| PRE-CAPILLARY | ||
| Group 1 (PAH) pulmonary arterial hypertension | Obliterative / proliferative | Idiopathic, connective tissue disease, HIV (human immunodeficiency virus), schistosomiasis |
| Group 3 (lung disease / hypoxia) | (not keyed) | COPD (chronic obstructive pulmonary disease), interstitial lung disease, sleep apnea |
| Group 4 chronic thromboembolic pulmonary hypertension (CTEPH) | Obstructive | Chronic thromboembolic occlusion |
| POST-CAPILLARY | ||
| Group 2 (left heart disease) | Passive | Obstruction to pulmonary venous outflow (heart failure with reduced or preserved ejection fraction, mitral stenosis) |
| DRAWN APART | ||
| Group 5 (unclear / multifactorial) | Complex | Hematologic, systemic, metabolic disorders (e.g., sarcoidosis) |
| Slide 19 prints a venous mechanism for Group 3; slides 6 and 15 explain it by hypoxic vasoconstriction. Only Group 2 is post-capillary. | ||
Arteries, Heart, Lungs, Clots, Unclear: “A Heart Loves Clean Understanding.” (His version: 1 arterial, 2 left heart, 3 lung, 4 clots.)
A (1) arterial: pulmonary arterial hypertensionH (2) left heart disease (post-capillary)L (3) lung disease / hypoxiaC (4) clots: chronic thromboembolicU (5) unclear / multifactorial (sarcoidosis)
Where it breaks: The hook does not tell you which groups are pre-capillary (1, 3, 4) and which is post-capillary (2).
| Stage (World Health Organization class) | Symptoms |
|---|---|
| Early / mild (I–II) | Exertional dyspnea and fatigue: often the only early symptom; misattributed to deconditioning |
| Moderate (III) | Dizziness, lightheadedness; marked limitation of physical activity |
| Severe (IV) | Syncope/presyncope = ominous (a fixed, low cardiac output that cannot rise with exertion); end-stage abdominal bloating, early satiety, edema; present even at rest |
Walk, Wobble, Wipe-out: breathless on walking (I–II), dizzy (III), fainting and full of fluid at rest (IV).
Walk exertional dyspnea, fatigue: class I–IIWobble dizziness, lightheadedness: class IIIWipe-out syncope, bloating, early satiety, edema at rest: class IV
Where it breaks: The slide 25 risk table gives “occasional syncope” to the intermediate tier (class III); repeated syncope is high risk.
| Left heart failure | Right heart failure / cor pulmonale | |
|---|---|---|
| Predominant symptoms | Orthopnea, paroxysmal nocturnal dyspnea | Abdominal bloating, early satiety, profound fatigue, exertional syncope |
| Lungs & chest X-ray | Bibasilar crackles, wheezing, Kerley B lines, pleural effusions | Lungs typically clear; enlarged central pulmonary arteries with peripheral pruning |
| Key hemodynamics | Wedge pressure >15 mmHg | Normal/low wedge (≤15 mmHg) with elevated mean pulmonary arterial pressure |
| Slide 33 draws its edema line at 18 (cardiogenic >18–20, noncardiogenic ≤18); each cut-off answers its own question. | ||
Left = Lungs wet; Right = the Rest (belly, liver, legs) wet and the lungs dry.
Left orthopnea, crackles, Kerley B, effusions, wedge >15Right bloating, satiety, clear lungs, pruned periphery, wedge ≤15
Where it breaks: The hook does not hold the number: 15 mmHg is the split on this slide.
| Determinant | Low (<5%) | Intermediate (5–10%) | High (>10%) |
|---|---|---|---|
| Signs of right ventricular failure | Absent | Absent | Present |
| Progression | Slow | Moderate | Rapid |
| Syncope | No syncope | Occasional | Repeated |
| WHO (World Health Organization) functional class | I or II | III | IV |
| 6-minute walk distance | >440 m | 165–440 m | <165 m |
Learn the middle (his rule): class III, occasional syncope, moderate progression, 165–440 m. Better is low, worse is high; right ventricular failure signs = automatically high.
Middle intermediate 5–10%Right ventricular failure signs high risk, >10%440 / 165 the walk-distance edges
Where it breaks: Right ventricular failure signs are absent in BOTH low and intermediate, so they only separate high from the rest.
| Pathway | Action | Examples |
|---|---|---|
| Endothelin receptor antagonists | Block endothelin-1: no potent vasoconstriction, no smooth muscle proliferation | Ambrisentan, bosentan, macitentan |
| ★ Phosphodiesterase-5 inhibitors | Prevent cGMP (cyclic guanosine monophosphate) breakdown, enhancing the nitric oxide pathway: smooth muscle relaxation | Sildenafil, tadalafil |
| Prostacyclins / IP receptor agonists | Increase cAMP (cyclic adenosine monophosphate); most potent class for vasodilation and anti-platelet aggregation; essential for severe disease | Epoprostenol, treprostinil, iloprost, selexipag |
Read the suffix: -AFIL = phosphodiesterase-5 (his “AFILs”); -SENTAN = endothelin; PROST in the name = prostacyclin (his rule).
-afil sildenafil, tadalafil-sentan ambrisentan, bosentan, macitentanprost epoprostenol, treprostinil, iloprost
Where it breaks: Selexipag is a prostacyclin-pathway (IP receptor) drug without “prost” in its name.
| Decision | Therapy |
|---|---|
| Vasoreactive | High-dose oral calcium channel blockers |
| Not vasoreactive, low / intermediate risk (class II/III) | Oral combination (endothelin receptor antagonist + phosphodiesterase-5 inhibitor); early combination beats sequential monotherapy |
| Not vasoreactive, high risk (class IV or rapid decline) | Continuous IV or subcutaneous parenteral prostanoids (epoprostenol) |
| Refractory to maximal therapy (or pulmonary veno-occlusive disease) | Lung transplantation, the only definitive option; IV support as a bridge (slide 29) |
| Foundations for everyone (slide 27): careful diuresis, oxygen for PaO2 (arterial oxygen pressure) >60 mmHg, supervised rehabilitation (no strict bedrest), annual influenza and pneumococcal vaccines. | |
Responders get a pill (calcium channel blocker); the rest get Two pills or a Drip: two oral drugs for class II–III, a prostanoid infusion for class IV.
Responder vasoreactive → high-dose oral calcium channel blockerTwo pills low/intermediate → oral combinationDrip high risk → IV or subcutaneous prostanoid
Where it breaks: The slide’s critical rule (no single variable decides) and its intensive-care example are left out.
| Cardiogenic | Noncardiogenic | |
|---|---|---|
| THE GREAT DIVIDE (slide 33) | ||
| Mechanism | Intact capillaries, extreme hydrostatic backup | Shattered endothelium leaking protein-rich fluid |
| Wedge pressure | >18–20 mmHg | ≤18 mmHg |
| Primary defect | The pump is failing | The pipe is leaking |
| CAUSES (slide 34) | ||
| Roots | Systolic dysfunction (ischemic, reduced ejection fraction); diastolic dysfunction (stiffening, aging, preserved ejection fraction); valvular lesions | Acute respiratory distress syndrome; sepsis; inhaled toxins |
| FLASH EDEMA (slide 46) | ||
| Drivers | Acute myocardial infarction, severe hypertension, chronic heart failure decompensation | Acute respiratory distress syndrome, high altitude, sepsis, toxins |
| Cardiac status | Enlargement / dysfunction common | Cardiac function typically normal |
| Slide 38: wedge >18–20 confirms cardiogenic failure. Slide 23’s cut-off for left heart failure is 15. | ||
Pump or Pipe? (His first question: “pipes, pumps, or filter?”) A failing Pump pushes the wedge over 18; a leaking Pipe keeps it at 18 or under.
Pump cardiogenic, wedge >18–20Pipe noncardiogenic (permeability), wedge ≤18
Where it breaks: A wedge above 15 and up to 18 is left-heart by slide 23 but noncardiogenic by slide 33.
| Condition | What distinguishes it |
|---|---|
| Heart failure (cardiogenic edema) | Highly elevated BNP (B-type natriuretic peptide); echo abnormalities; Kerley B lines |
| Pulmonary embolism (the blocked pipe) | Clear lungs on chest X-ray; normal BNP initially; S1Q3T3 or right ventricular strain |
| COPD (chronic obstructive pulmonary disease) exacerbation (the inflamed airway) | Wheezing / hyperinflation; hypercapnia; usually normal BNP |
| Shared by all three: dyspnea, hypoxemia, tachycardia. BNP = B-type natriuretic peptide. | |
BNP high = Heart; Clear film + S1Q3T3 = Clot; CO2 high + wheeze = COPD.
BNP heart failureClear + S1Q3T3 pulmonary embolismCO2 + wheeze COPD exacerbation
Where it breaks: BNP is normal in both embolism (initially) and COPD; the film and the gas separate those two.
| Letter | Intervention |
|---|---|
| L – Loop diuretics (IV) | Rapid volume reduction; aggressive diuresis (furosemide, bumetanide, torsemide) |
| M – Morphine | Use with caution. Historically used for venodilation and anxiolysis, but carries respiratory depression risk |
| N – Nitrates (IV) | Immediate preload and afterload reduction via potent venodilation |
| O – Oxygen / upright positioning | Better ventilation/perfusion matching; gravity drops venous return |
| P – Positive airway pressure | Noninvasive ventilation: alveolar stenting and preload reduction |
| Flash edema (slide 46): upright with legs dangling; IV furosemide; IV nitrates; CONTINUE oral beta-blockers unless in shock; hold outpatient therapy during acute kidney injury. | |
LMNOP, “like my toolbox, not a checklist”: use only the tools the patient needs.
L loop diureticsM morphine (caution)N nitratesO oxygen / uprightP positive airway pressure
Where it breaks: Slide 46 says nitrates “rapidly reduce afterload”; slide 39 says preload and afterload. Current guidelines advise against routine morphine.
| Stage | Meaning | Focus |
|---|---|---|
| A & B | At risk and pre-symptomatic | Prevention and risk modification |
| C | Clinical heart failure | Quadruple therapy (angiotensin receptor-neprilysin inhibitor [ARNI], beta-blocker, mineralocorticoid receptor antagonist, sodium-glucose cotransporter-2 [SGLT-2] inhibitor) |
| D | Marked symptoms at rest despite maximal medical therapy; frequent hospitalizations | Referral trigger: heart transplant, mechanical circulatory support (left ventricular assist device), or palliative hospice care |
A and B Before symptoms; C = Clinical (the four drugs); D = Done with what drugs can do: refer.
A/B at risk, pre-symptomaticC clinical, quadruple therapyD refractory: transplant, assist device, hospice
| Hypercoagulability | Venous stasis | Endothelial injury |
|---|---|---|
| Malignancy | Prolonged immobilization (>8 hr flights) | Recent surgery |
| Estrogen therapy | Bed rest | Central venous catheters |
| Pregnancy | Paralysis | Pacemaker wires |
| Genetic thrombophilias | Heart failure (New York Heart Association III/IV) | Pelvic / lower limb trauma |
| Sepsis | ||
| “Inability to identify a known clinical predisposition should never dissuade an objective evaluation.” | ||
Thick blood, Still blood, Torn vessel: the clot needs one good reason, not fifteen (his: “I just need a couple of good ones”).
Thick hypercoagulability: cancer, estrogen, pregnancy, thrombophilia, sepsisStill stasis: flights, bed rest, paralysis, heart failureTorn endothelial injury: surgery, catheters, pacemaker wires, trauma
| Syndrome | Features | Means |
|---|---|---|
| Isolated dyspnea | Sudden, minutes to hours; at rest or only with exertion | |
| Pleuritic pain & hemoptysis | Often a localized friction rub | Distal, pleural-based infarction |
| Circulatory collapse | Syncope, severe hypotension, obstructive shock | Massive, proximal occlusion |
| ★ The dyspnea trap: about 25% of proven pulmonary embolisms completely lack dyspnea. | ||
Breath, Blood, Bust: short of breath, coughing blood with a pleuritic pain, or busted circulation.
Breath isolated dyspneaBlood hemoptysis + pleuritic pain = distal infarctionBust collapse = massive proximal clot
Where it breaks: One in four has no “Breath” at all.
| Sign | What it is | Meaning |
|---|---|---|
| ★ S1Q3T3 | Deep S in lead I; Q wave and inverted T in lead III | Severe right ventricular strain, not purely embolism; highly specific, low sensitivity |
| Westermark sign | Focal peripheral oligemia (decreased vascularity) | Classic, infrequent |
| Hampton’s hump | Wedge-shaped, pleural-based opacity | Infarction |
| Palla sign | Enlarged right descending pulmonary artery | Classic, infrequent |
| Most chest films in embolism are abnormal but nonspecific (atelectasis, effusion). | ||
Westermark = a Wasteland (no vessels); Hampton’s Hump = a Hill-shaped wedge at the pleura; Palla = a Plump Pulmonary artery. S1Q3T3 = “S one, Q three, T three.”
Wasteland Westermark: oligemiaHump Hampton: wedge, infarctionPlump Palla: big right descending artery
Where it breaks: The hook says nothing about sensitivity: S1Q3T3 is specific but not sensitive; the film signs are suggestive but uncommon.
| Points | Criterion |
|---|---|
| HIGH WEIGHT | |
| +3.0 | Clinical signs and symptoms of deep venous thrombosis |
| +3.0 | Pulmonary embolism is the #1 diagnosis (more likely than alternatives) |
| +1.5 | Heart rate >100 bpm |
| +1.5 | Immobilization (>3 days) or surgery in previous 4 weeks |
| LOWER WEIGHT | |
| +1.5 | Previous deep venous thrombosis or pulmonary embolism |
| +1.0 | Hemoptysis |
| +1.0 | Malignancy (on treatment, treated in last 6 months, or palliative) |
| TOTAL | |
| ≤4 | Unlikely → PERC (Pulmonary Embolism Rule-out Criteria), then D-dimer |
| >4 | Likely → straight to CT pulmonary angiography |
3 for the Clot you see and the Clinician’s pick; 1.5 for the Heart rate, being Held down (immobile or surgery) and a History of clot; 1 for Hemoptysis and Hostile cells (cancer).
3 + 3 deep venous thrombosis signs; embolism the #1 diagnosis1.5 × 3 heart rate >100; immobilization >3 days or surgery within 4 weeks; previous clot1 + 1 hemoptysis; malignancy4 ≤4 unlikely, >4 likely
Where it breaks: The slide files previous clot under “lower weight” though it scores 1.5, the same as heart rate; learn the points. A total of exactly 4 is unlikely.
| Criterion | Criterion |
|---|---|
| LAYER 1: THE PERC RULE (all eight true = stop) | |
| Age <50 | No exogenous estrogen |
| Heart rate <100 | No prior venous thromboembolism |
| O2 (oxygen) saturation >94% | No surgery / trauma |
| No hemoptysis | No unilateral leg swelling |
| For very low clinical gestalt (<15%). If all true, STOP workup. | |
| LAYER 2: HIGHLY SENSITIVE D-DIMER | |
| Who gets it | Low/intermediate probability patients who fail PERC |
| Performance | High sensitivity, low specificity |
| Negative | A negative ELISA (enzyme-linked immunosorbent assay) D-dimer safely excludes pulmonary embolism |
| Positive | Proceed to imaging |
| These tools are designed to rule OUT disease in outpatients; D-dimer has limited utility in inpatients (universally high false-positive rates). | |
HAD CLOTS: any one of these and PERC fails.
H Hormones (exogenous estrogen)A Age 50 or overD Deep venous thrombosis or pulmonary embolism before (prior venous thromboembolism)C Coughing blood (hemoptysis)L Leg swelling, one sideO O2 saturation ≤94%T Tachycardia (heart rate ≥100)S Surgery or trauma
Where it breaks: PERC is used only after Wells says unlikely; an older patient can never pass it.
| CT pulmonary angiography | V/Q scan | |
|---|---|---|
| Best used for | First-line imaging for almost all patients | Renal dysfunction, severe contrast allergy, critically ill (portable bedside perfusion scan) |
| Limitations | IV iodinated contrast; radiation; overdiagnosis of insignificant subsegmental emboli | Frequently nondiagnostic with underlying cardiopulmonary disease (chronic obstructive pulmonary disease, severe heart failure) |
| A completely negative V/Q scan excludes embolism with the same certainty as a negative pulmonary angiogram. Echo (slide 56): poor sensitivity (~50%) for embolism, very high specificity for right ventricular strain: stratification, not diagnosis. | ||
CT for everyone; V/Q when the Kidneys or the contrast allergy say no, or the patient cannot travel.
CT first lineV/Q renal dysfunction, contrast allergy, critically ill
Where it breaks: Chronic obstructive pulmonary disease or severe heart failure points back to CT, because the V/Q scan is often nondiagnostic.
| Branch | Next step |
|---|---|
| Wells ≤4 (unlikely) | PERC (Pulmonary Embolism Rule-out Criteria): pass → stop; fail → D-dimer: negative → ruled out; positive → CT pulmonary angiography |
| Wells >4 (likely) | Bypass D-dimer: direct to CT pulmonary angiography (or a ventilation/perfusion [V/Q] scan if contrast is contraindicated) |
| Positive CT or high-probability V/Q | Diagnosis confirmed → assess hemodynamic stability / right ventricular strain |
Wells first, always (his words: “It’s not an either-or. Wells first”). Low road: PERC, then D-dimer, then CT. High road: straight to CT.
Low road ≤4: PERC → D-dimer → CTHigh road >4: CT (or V/Q)
Where it breaks: He wants the decision points, not every box of the chart.
| Category | Criteria | Implication |
|---|---|---|
| Low-risk | Normotensive, NO right ventricular dysfunction, negative cardiac biomarkers | Excellent prognosis, standard anticoagulation |
| Submassive / intermediate | Normotensive (systolic >90) BUT right ventricular dysfunction (echo/CT) or myocardial necrosis (elevated troponin/BNP) | High risk for sudden deterioration |
| Massive / high-risk | Sustained hypotension (systolic <90 for >15 min), pulselessness, or profound bradycardia; circulatory collapse | High mortality; immediate advanced intervention |
Pressure first, then the heart: low pressure = Massive; normal pressure but a strained or bruised right ventricle = Submassive (“know the one in the middle”); all normal = Low.
Pressure low massivePressure fine, RV (right ventricular) or troponin bad submassiveAll fine low-risk
Where it breaks: Current European guidance splits the middle tier into intermediate-high and intermediate-low; the slide (and the exam) keeps three.
| Situation | Treatment |
|---|---|
| ANTICOAGULATION (slide 59) | |
| Confirmed (or high suspicion while awaiting imaging) | Start anticoagulation immediately |
| Transient / provoked (recent surgery, trauma, hospitalization, estrogen) | Consider stopping after 3 months |
| Persistent / unprovoked (active malignancy, hypercoagulable state, no risk factor) | Indefinite anticoagulation |
| ADVANCED INTERVENTIONS (slide 60) | |
| Massive (hemodynamically unstable) | Thrombolysis (systemic or catheter-directed): “the gold standard” |
| Massive + absolute contraindication (recent surgery, active bleeding) or right heart clot in transit | Mechanical thrombectomy or surgical embolectomy |
| Submassive | Thrombolysis highly controversial (bleeding, intracranial hemorrhage) |
| Deep venous thrombosis and embolism are treated alike: halt propagation, allow endogenous fibrinolysis. The slides name no drug. | |
Provoked Pauses at 3 months, Unprovoked is Unending; the Unstable get Lysed, unless they can’t bleed safely or the clot is in transit: then Pull it out.
Pause provoked: 3 monthsUnending unprovoked: indefiniteLyse massivePull thrombectomy / embolectomy when lysis is contraindicated
Where it breaks: Submassive is neither: anticoagulate, and lysis is debated.
| Finding at 3 months of anticoagulation | Next step |
|---|---|
| No dyspnea | Length of anticoagulation by recurrence risk |
| Persistent or worsening dyspnea | V/Q (ventilation/perfusion) scan |
| V/Q normal | Back to the length decision |
| V/Q abnormal | Transthoracic echo, right heart catheterization, pulmonary angiogram; refer to an expert center; continue anticoagulation |
| Risk factors: unprovoked embolism, diagnosis delayed >2 weeks, right ventricular dysfunction on the first CT, recurrent embolism. ★ Optimal treatment: surgical (pulmonary thromboendarterectomy). | |
Still breathless at 3 months? Scan (V/Q), then Send (expert center), then Surgery (thromboendarterectomy).
3 months screen for dyspneaScan V/QSend echo, catheterization, angiogram, expert centerSurgery thromboendarterectomy
| Concerning nodules are | Benign nodules tend to |
|---|---|
| Greater than 6 mm | Smaller than 6 mm (not concerning unless the patient is high risk) |
| Located in the upper lobes or hilar structures | Sit close to a fissure (usually benign) |
| Spiculated (spikes or deviations or lobulations in the border) | Have well-defined borders (smoothly marginated) |
| More than 3 nodules; enlarging over time | Have fatty tissue (hamartoma) |
| Contrast enhanced on CT; cavitated or nonsolid | Have calcifications (popcorn = hamartoma; central = healed granuloma) |
| Patient at high risk of lung cancer | Most nodules are benign: granuloma (inflammatory), hamartoma (connective tissue growth) |
| Slide 16 also says “close to … the pleura” is usually benign, but slide 32’s nodule that involved the pleura was an invasive adenocarcinoma: only the fissure is keyed. Positron emission tomography: low or normal uptake is a good sign (slide 17). | |
“Magic number is 6”, then BUSTED: Big (over 6 mm), Upper lobe or hilar, Spiculated, Three-plus nodules, Enlarging or Enhancing, Dug-out (cavitated) or nonsolid, plus a high-risk patient.
Big greater than 6 mmUpper upper lobes or hilar structuresSpiculated spiky borderThree-plus more than 3 nodulesEnlarging / Enhancing growing over time; contrast enhanced on CTDug-out cavitated or nonsolid
Where it breaks: The high-risk patient has no letter in BUSTED. The benign column has no letters: smooth, fat, calcium (popcorn), fissure.
| Pattern | Benign or malignant |
|---|---|
| Diffuse | Benign |
| Central | Benign |
| Popcorn | Benign (hamartoma) |
| Concentric | Benign |
| Ground-glass (stippled) | Malignant |
| Eccentric | Malignant |
Benign calcium is Dense, Centered, Popped or in Circles (DCPC); malignant calcium is Grainy or Off-center.
D diffuseC centralP popcorn (hamartoma)C concentric (circles)Grainy ground-glass, stippled: malignantOff-center eccentric: malignant
| Clinical probability of malignancy | Next step |
|---|---|
| Very low (< 5%) | CT surveillance at 3–6, 9–12, 18–24 months (low-dose, thin sections, noncontrast CT) |
| Low/moderate (5% to 65%) | FDG-PET (fludeoxyglucose positron emission tomography): negative or mild uptake → the same CT surveillance; moderate or intense uptake† → nonsurgical biopsy (transthoracic needle, endoscopic) or video-assisted thoracoscopic surgery with resection |
| High† (> 65%) | Standard stage evaluation (with or without FDG-PET) → no metastases → video-assisted thoracoscopic surgery with resection |
| Probability by clinical judgment and/or a validated model. † Referral to a pulmonologist, thoracic surgeon, interventional radiologist or oncologist is recommended. He: “Don’t lose sleep over [the probability tables], just know you’re gonna work it up.” | |
Low → Look (CT surveillance); Middle → Measure the sugar (PET); High → Hand it to surgery (stage, then resection).
Look very low: CT at 3–6, 9–12, 18–24 monthsMeasure low/moderate: FDG-PET, then surveillance or biopsy/resectionHand high: staging, then video-assisted thoracoscopic resection
Where it breaks: Referral (the dagger) applies to both the high branch and the moderate/intense uptake branch.
| Criterion | Slide 18 |
|---|---|
| Who | High-risk adults without symptoms or a known nodule |
| Age | 55 to 80 |
| Smoking | At least 30 pack-years |
| Status | Smokes now, or quit within the last 15 years |
| Test | Low-dose chest CT every year (less radiation than a standard chest CT) |
| Upside / downside | Early detection, better prognosis / false positives → unnecessary workup with complications (such as a biopsy) |
| Medicare only covers 55 to age 77 (slide 18). Current guidelines differ: the 2021 update is 50–80 with 20 pack-years; the slide’s numbers are what is tested. Symptoms mean a diagnostic workup, not screening. | |
55, 30, 15, 1: age 55 (to 80), 30 pack-years, quit within 15 years, 1 low-dose CT a year.
55 age 55 to 8030 at least 30 pack-years15 smoking now or quit within 15 years1 one low-dose chest CT every year
Where it breaks: The upper age (80) and the no-symptoms rule are outside the numbers.
| Nodule type | <6 mm | 6–8 mm | >8 mm |
|---|---|---|---|
| Single, low risk | No routine follow-up | CT at 6–12 months, then consider CT at 18–24 months | Consider CT at 3 months, PET/CT, or tissue sampling |
| Single, high risk | Optional CT at 12 months | CT at 6–12 months, then CT at 18–24 months | Consider CT at 3 months, PET/CT, or tissue sampling |
| Multiple, low risk | No routine follow-up | CT at 3–6 months, then consider CT at 18–24 months | CT at 3–6 months, then consider CT at 18–24 months |
| Multiple, high risk | Optional CT at 12 months | CT at 3–6 months, then at 18–24 months (underlined in class) | CT at 3–6 months, then at 18–24 months |
| He said not to memorize it (“they literally will publish the Fleischner table in those reports”), then read these rows aloud. Comments: low-risk nodules <6 mm need no routine follow-up; high-risk patients with suspicious morphology or an upper lobe location may warrant 12-month follow-up; with multiple nodules, use the most suspicious as the guide. | |||
Under 6: low risk Leave it, high risk an Optional look at a year. Over 8: 3 months, PET or tissue. In between: single starts at 6–12, multiple at 3–6, and everyone ends at 18–24.
Leave it <6 mm, low risk: no routine follow-upOptional <6 mm, high risk: optional CT at 12 monthsOver 8 single: CT at 3 months, PET/CT or tissue sampling6–12 / 3–6 first CT for single / multiple 6–8 mm18–24 the second CT
Where it breaks: Multiple nodules over 8 mm follow the 3–6 then 18–24 month rule, not the single-nodule “3 months, PET or tissue”; low-risk rows say “consider” for the second CT.
| Nodule type | <6 mm | ≥6 mm |
|---|---|---|
| Single, ground glass | No routine follow-up | CT at 6–12 months to confirm persistence, then CT every 2 years until 5 years |
| Single, part solid | No routine follow-up | CT at 3–6 months to confirm persistence; if unchanged and the solid part stays <6 mm, annual CT for 5 years |
| Multiple | CT at 3–6 months; if stable, consider CT at 2 and 4 years | CT at 3–6 months; then manage by the most suspicious nodule(s) |
| Persistent part-solid nodules with a solid component ≥6 mm are highly suspicious. Multiple pure ground-glass nodules <6 mm are usually benign. He: “there’s rules, you’re fine”; not on his slide 49 list. | ||
Glass is slow (6–12 months, then every 2 years to 5); a Solid part speeds it up (3–6 months, then yearly to 5); a solid part of 6 mm or more that persists = Suspicious.
Glass ground glass ≥6 mm: CT 6–12 months, then every 2 years until 5 yearsSolid part part solid ≥6 mm: CT 3–6 months, then annual CT for 5 yearsSuspicious persistent solid component ≥6 mm
Where it breaks: Single nodules under 6 mm need no routine follow-up; the multiple row has its own schedule.
| Fit for surgery? | Path | End point |
|---|---|---|
| First: PET-CT for staging (if not already performed) | ||
| Yes | Wedge resection with on-table frozen section | Completion lobectomy under the same anesthetic |
| Yes | Image-guided biopsy → malignancy confirmed | Lobectomy, or anatomical segmentectomy if unfit for lobectomy |
| No | Image-guided biopsy if possible and safe → malignancy confirmed | SABR (stereotactic ablative radiotherapy), RFA (radiofrequency ablation) or conventional radical radiotherapy |
| No | Biopsy not possible or not safe | Straight to SABR, RFA or radical radiotherapy |
| A negative biopsy: consider repeat biopsy, or proceed if a false negative is feared. The fit path may also go straight to anatomical segmentectomy if unfit for lobectomy. | ||
Fit = Cut (wedge, lobe, or segment if the lobe is too much); Unfit = Zap (ablate or radiate), biopsy first only if Safe.
Cut resection: wedge then completion lobectomy, lobectomy, or segmentectomy if unfit for lobectomyZap SABR, RFA or conventional radical radiotherapySafe image-guided biopsy only if possible and safe
| Category | Slide 22 |
|---|---|
| PRIMARY TUMOR | |
| T1 | ≤ 3 cm, not involving the main bronchus (1a ≤ 1, 1b >1–2, 1c >2–3 cm) |
| T2 | >3 to ≤5 cm, or main bronchus (not carina), visceral pleura, or atelectasis/post-obstructive pneumonitis to the hilum (2a >3–4, 2b >4–5 cm) |
| T3 | >5 to ≤7 cm, or chest wall, pericardium, phrenic nerve, or satellite nodules in the same lobe |
| T4 | >7 cm, or mediastinum, diaphragm, heart, great vessels, recurrent laryngeal nerve, carina, trachea, esophagus, spine, or a tumor in a different lobe of the same lung |
| LYMPH NODES | |
| N1 | Ipsilateral peribronchial and/or hilar and intrapulmonary nodes |
| N2 | Ipsilateral mediastinal and/or subcarinal nodes |
| N3 | Contralateral mediastinal or hilar; ipsilateral/contralateral scalene/supraclavicular |
| METASTASIS | |
| M1a | Contralateral lung, or pleural/pericardial nodule or malignant effusion |
| M1b | Single extrathoracic metastasis (including a single non-regional node) |
| M1c | Multiple extrathoracic metastases |
| N2 or N3 automatically moves it to stage 3; all stage 1–3 tumors are M0 (slide 25). Slide 31’s “M1 or 2”: there is no M2. | |
T climbs 3-5-7 (cm); N climbs Near-Middle-Far (hilar, mediastinal, other side or neck); M is a = still in the chest, b = one outside, c = many outside.
3-5-7 T1 ≤3, T2 >3–5, T3 >5–7, T4 >7 cmNear N1 same-side hilar/peribronchialMiddle N2 same-side mediastinal/subcarinalFar N3 other side, or scalene/supraclaviculara / b / c M1a chest (other lung, pleura, pericardium, effusion), M1b single extrathoracic, M1c multiple
Where it breaks: Invasion of structures (chest wall for T3; mediastinum, heart, carina and others for T4) raises T regardless of size.
| Stage | Tumor and nodes, as the pictures state them |
|---|---|
| 1A | ≤ 3 cm, no nodes |
| 1B | >3 to 4 cm, no nodes |
| 2A | >4 to 5 cm, no nodes |
| 2B | >5 to 7 cm, no nodes (or chest wall, phrenic nerve, heart lining, same-lobe tumor); or ≤5 cm with peribronchial or hilar nodes |
| 3A | >7 cm or diaphragm/mediastinal invasion or other-lobe tumor, no nodes; or >5 cm with same-side peribronchial/hilar nodes; or ≤5 cm with mediastinal (subcarinal) nodes |
| 3B | >5 cm with same-side mediastinal nodes; or ≤5 cm with other-side nodes or any supraclavicular or scalene node |
| 3C | >5 cm with other-side nodes or any supraclavicular or scalene node |
| 4A | Any size: the other lung, the pleura or pericardium (nodules or fluid), or one site outside the chest (adrenal) |
| 4B | Any size: multiple sites outside the chest (adrenal and bone) |
| He: “Size of the tumor is badness. Lymph node involvement, badness. Metastasis, worse badness”; crossing to the other lung is badness. Big picture, not every circumstance. | |
Stage 1 = small, no nodes; 2 = bigger or the first (hilar) nodes; 3 = middle (mediastinal) or far (other side, neck) nodes; 4 = it left: the other lung, the pleura, or outside the chest (A = one site, B = many).
1 ≤4 cm, no nodes (1A ≤3, 1B >3–4)2 >4–7 cm, no nodes, or small with hilar/peribronchial nodes3 N2 or N3 nodes, >5 cm with hilar/peribronchial nodes, or >7 cm / invasion4 M1: 4A one site outside the chest or within the chest; 4B multiple sites
Where it breaks: Stage 3A also holds a tumor over 7 cm (or invading the diaphragm or mediastinum) with no nodes at all.
| Cancer type | Most common location |
|---|---|
| Small cell | Central, but usually metastatic by the time of diagnosis |
| Squamous cell carcinoma | Central bronchi; can diagnose via sputum cytology |
| Adenocarcinoma | Periphery (not amenable to early detection) |
| Large cell carcinoma | Periphery (not amenable to early detection) |
| Mixed types exist (adenosquamous, combined small cell). Slide 9: most masses form in or near the hilum, some in the periphery (hard to diagnose). | |
His own: “Small and squamous are central”: the two S’s Sit in the center; the other two go to the edges.
S Small cell: centralS Squamous cell: centralEdges adenocarcinoma and large cell: periphery
| Stage | Standard management |
|---|---|
| 1A and B | Surgical resection |
| 2A and B | Surgical resection |
| 3A | Chemoradiotherapy, surgical resection in selected patients |
| 3B | Chemoradiotherapy |
| 4 | Cisplatin-based chemotherapy (slide: “Ciplatin”); surgical resection only if a solitary metastatic lesion with a resectable primary tumor |
| Slide 35 text: resection (wedge/segment, lobectomy, pneumonectomy) by size and nodes, “(I–IIIB)”, if the patient can tolerate it; chemotherapy and radiation only as adjuncts or for stage 4, as non-small cell cancers respond poorly. Text and table differ for stage 3: never asked. | |
1 and 2: Cut. 4: Chemo. 3: the slide argues with itself.
Cut stages 1–2: surgical resectionChemo stage 4: chemotherapy (surgery only for a solitary metastasis with a resectable primary)3 text says resection to 3B; table says chemoradiotherapy (3A, selected surgery)
| Item | What the slides say |
|---|---|
| CATEGORIES (slide 41) | |
| Limited stage | Confined to one area with only local lymph nodes |
| Extensive stage | Spread away from the local area |
| Combined | Different histological types, mixed with non-small cell |
| COMPLETE OR PARTIAL RESPONSE (slide 43) | |
| Limited stage | Prophylactic cranial irradiation (PCI) (category 1) |
| Extensive stage | Consider PCI ± thoracic radiotherapy |
| Brain MRI (magnetic resonance imaging) is preferred over CT; PCI is not recommended with poor performance status or impaired neurocognitive function. Radiation works best in limited stage (slide 41). Follow-up visit schedule: “don’t memorize that.” | |
Limited gets the Lid (PCI, a cap of radiation on the brain); Extensive only Entertains it (consider PCI ± chest radiation).
Lid limited stage: PCI after a complete or partial responseEntertains extensive stage: consider PCI ± thoracic radiotherapy
Where it breaks: Combined (mixed histology) has no letter; the hook covers the response branch only.
| System | Syndrome | Linked type |
|---|---|---|
| Endocrine | SIADH (syndrome of inappropriate antidiuretic hormone): low sodium and osmolality → confusion, seizures, ataxia, no edema | Small cell (slide 48) |
| Endocrine | Hypercalcemia | Squamous cell (“particularly”) |
| Neurological | Lambert-Eaton myasthenic syndrome (autoimmune; calcium channels at the nerve ending, no acetylcholine release → leg weakness); cerebellar degeneration or encephalitis | Not tied to one type |
| Dermatological | Acanthosis nigricans or dermatomyositis | Not tied to one type |
| Hematological | Listed; no example given | — |
| Carcinoid syndrome | Serotonin: flushing, pulmonic and tricuspid valve thickening, wheeze, diarrhea | Bronchial carcinoid |
| Slide 46 tags Lambert-Eaton “central” and cerebellar degeneration “peripheral”; slide 47 places Lambert-Eaton at the neuromuscular junction: the tags are never keyed. | ||
Small cell Secretes Sodium-lowering hormone; Squamous Spikes calcium; Carcinoid Causes flushing.
Small → Sodium small cell → SIADH (hyponatremia)Squamous → Spikes calcium squamous → hypercalcemiaCarcinoid → flushing bronchial carcinoid → serotonin (carcinoid syndrome)
Where it breaks: The neurologic and skin syndromes are not tied to a cell type on the slides.
| Parietal pleura | Visceral pleura | |
|---|---|---|
| Where | Lines the thoracic cavity, diaphragm and mediastinum | Covers the lungs |
| Blood supply | Systemic circulation | Pulmonary circulation |
| Hydrostatic pressure | Higher | Lower |
| Sensory nerves | Intercostal and phrenic nerve fibers | None |
| Pleurisy is inflammation of the parietal pleura: the layers rub and stimulate its pain fibers (slide 9). The central diaphragm is phrenic territory, so its pain refers to the ipsilateral shoulder or neck (slide 11). | ||
Parietal = Pain and Pressure (and the body’s own Systemic blood); Visceral = Voiceless (no sensory nerves).
Pain parietal: intercostal and phrenic nerve fibersPressure parietal: higher hydrostatic pressure, systemic supplyVoiceless visceral: no sensory innervation, pulmonary supply, lower pressure
| Feature | Normal |
|---|---|
| Volume | 10 mL (2 teaspoons) in a potential space (slide 4) |
| Appearance | Clear ultrafiltrate of plasma; from parietal capillaries, removed by parietal lymphatics |
| pH | 7.60–7.64 |
| Protein | Less than 1–2 g/dL |
| White blood cells | Under 1000, mostly macrophages |
| Glucose | Similar to plasma |
| Lactate dehydrogenase | Under 50% of plasma |
Ten clear mL, then count down: 7.6, 1–2, 1000, same, half.
10 mL, clear ultrafiltrate of plasma7.6 pH 7.60–7.641–2 protein under 1–2 g/dL1000 white cells under 1000, mostly macrophagesSame glucose similar to plasmaHalf lactate dehydrogenase under 50% of plasma
| Type | Definition | Who / examples |
|---|---|---|
| Spontaneous, primary | No thoracic trauma; no underlying lung abnormality | Tall, thin young males, 20–40; male > female; smoking; family history; good reserve (slide 19) |
| Spontaneous, secondary | No thoracic trauma; underlying lung abnormality | Chronic obstructive pulmonary disease (most common; apical blebs); lung malignancy (may be the first symptom); cystic fibrosis; pneumonia or tuberculosis; sarcoidosis; Marfan syndrome (slide 20) |
| Traumatic | History of thoracic trauma | Blunt or penetrating trauma; slide 61 adds cardiopulmonary resuscitation and mechanical ventilation |
| Iatrogenic | Injury to the pleura from a medical intervention | Thoracentesis, subclavian vein catheter placement, bronchoscopy, mechanical ventilation |
| ★ Board trap: a tall, thin young man with Marfan syndrome has a secondary pneumothorax (connective tissue disease). Mechanical ventilation is iatrogenic on slide 17 and traumatic on slide 61. | ||
His flat tire: primary “just blew”; secondary “I can explain the flat tire”; iatrogenic is “like trauma, but somebody with a license did it to you.”
Blew primary: no trauma, no lung diseaseExplain secondary: an underlying lung abnormality (including Marfan)Trauma blunt or penetratingLicense iatrogenic: thoracentesis, subclavian line, bronchoscopy, ventilator
Where it breaks: Mechanical ventilation fits both “trauma” and “license” on the slides.
| Size (American College of Chest Physicians) | Apex-to-cupola distance |
|---|---|
| Small | <3 cm |
| Large | ≥3 cm |
| The course measures apex to cupola (a, American); b, the interpleural distance at the hilum, is the British measure. The treatment slides word it as primary “<3 cm” vs “>3 cm” (slides 53–55) and secondary small “≤3 cm” (slide 56); the slide 58 picture uses percent (<20%, >25%). Current guidelines differ: the British Thoracic Society (2023) weighs symptoms over size. | |
“I like having a nice, easy number”: three centimeters from apex to cupola. Small is small, large is large.
<3 small≥3 largeApex–cupola the American measurement the course uses
| Stable = ALL of these (American College of Chest Physicians) | Cut-off |
|---|---|
| Respiratory rate | <24 breaths per minute |
| Heart rate | <120 and >60 beats per minute |
| Blood pressure | Normal (no number given) |
| Room air oxygen saturation | >90% |
| Speech | Able to speak in whole sentences |
| All other patients are considered unstable. “You can get two sentences, and look at the vitals … So don’t overthink it.” | |
Really Healthy Breathers Only Speak.
R Respiratory rate <24H Heart rate 60–120B Blood pressure normalO Oxygen saturation >90% on room airS Speaks in whole sentences
Where it breaks: Blood pressure is the one item without a number on the slide.
| Presentation | Treatment |
|---|---|
| PRIMARY | |
| Small (<3 cm at apex), asymptomatic or minimal symptoms (slide 53) | Observation; analgesia; 100% oxygen by non-rebreather (speeds resorption); repeat film at 6–12 hours; discharge if stable and asymptomatic; repeat film at 24–48 hours |
| Small with significant dyspnea after analgesia (slide 54) | Catheter aspiration; Heimlich valve or chest tube. Chest tube if observation fails (enlarging, respiratory rate >30, saturation <90% on room air) or aspiration fails |
| Moderate or large (>3 cm), moderate or severe symptoms (slide 55) | Chest tube insertion |
| Recurrent (slide 55) | Video-assisted thoracoscopic surgery with pleurodesis |
| SECONDARY | |
| Small (≤3 cm), asymptomatic or mild (slide 56) | Observation if asymptomatic; chest tube for symptoms or persistent air leak; hospitalization |
| In general: less reserve, more life-threatening (slide 57) | Most get a chest tube; thoracoscopic surgery or thoracotomy with bleb stapling and pleural abrasion; chemical pleurodesis via chest tube if surgery is not an option |
| The slide 58 picture differs: simple aspiration is “first-line” for symptomatic primary pneumothorax; stable patients are observed 4–6 hours; air leaks >72–96 hours go to surgery or a Heimlich valve (slide 60: surgical evaluation after 4 days). Slide 49 lists secondary pneumothorax as a surgical indication while slide 56 observes a small asymptomatic one. | |
Primary: Watch, Suck, Tube, Fix. Secondary: Admit and Tube.
Watch primary, small, minimal symptoms: observe, analgesia, 100% oxygen, film at 6–12 hoursSuck primary, small but still dyspneic: catheter aspirationTube primary, moderate or large (>3 cm) with symptoms: chest tubeFix primary, recurrent: thoracoscopic surgery with pleurodesisAdmit and Tube secondary: hospitalize; most get a chest tube
Where it breaks: A small asymptomatic secondary pneumothorax is only observed, but in hospital.
| Indication (slide 49) | Note |
|---|---|
| Recurrent spontaneous pneumothorax | With pleurodesis: the best preventive procedure (slide 59) |
| Bilateral pneumothorax | |
| Failure of tube thoracostomy | Lung fails to expand, or a persistent air leak |
| Secondary pneumothorax | High recurrence rates and greater consequences of recurrence |
| Risks: patient discomfort, general anesthesia, greater cost. Open thoracotomy (slide 50) stays for complicated cases: it lets the surgeon find the air leak and free adhesions. | |
Surgery for the pneumothorax that comes Back, comes in a Pair, Beats the tube, or sits on Sick lungs.
Back recurrentPair bilateralBeats the tube failed tube thoracostomy (no expansion, persistent leak)Sick lungs secondary
| # | Do NOT aspirate in |
|---|---|
| 1 | Traumatic pneumothorax |
| 2 | Tension pneumothorax |
| 3 | Hemodynamic instability |
| 4 | Underlying pulmonary disease |
| 5 | Recurrent pneumothorax |
| 6 | Bilateral pneumothoraces |
| 7 | Bleeding disorders |
Two Trucks Hit Us, Really Badly Bleeding.
T TraumaticT TensionH Hemodynamic instabilityU Underlying lung diseaseR RecurrentB BilateralB Bleeding disorders
Where it breaks: Read the list backward: aspiration suits a first, one-sided, primary pneumothorax in a stable patient.
| Procedure | Site |
|---|---|
| Needle decompression (needle thoracostomy) | Side of the pneumothorax; 2nd intercostal space, over the 3rd rib, midclavicular line (slide 68, “A”) |
| Catheter aspiration | Side of the pneumothorax; 2nd intercostal space, over the 3rd rib, midclavicular line |
| Chest tube | 4th or 5th intercostal space, midaxillary line (most common; slide 68, “B”); 2nd–3rd space at the midclavicular line for anterior access (less common, pneumothorax only; slide 73) |
| ★ “For test purposes for now, that would be the right answer”: 2nd space, midclavicular. Slide 68: “You have options; consider patient body habitus and choose wisely!” Current guidelines differ: Advanced Trauma Life Support (10th edition) moves the adult needle site to the 4th or 5th space just anterior to the midaxillary line. | |
Needles go high and in front; tubes go low and to the side.
High, front needle and aspiration: 2nd intercostal space, midclavicular lineLow, side chest tube: 4th or 5th intercostal space, midaxillary line
| Item | Slide wording |
|---|---|
| Mechanism (63) | Air enters the pleural space but cannot escape: a one-way valve |
| Findings (64) | Severe ventilatory compromise; mediastinal shift to the contralateral side → ↓ venous return and cardiac output; hypotension, tracheal deviation, neck vein distention; decreased/absent breath sounds |
| Diagnosis (66) | Clinical: time is critical, no time for the X-ray |
| Treatment (66) | Immediate chest tube is ideal; if not readily available, immediate needle decompression, followed by a moderate or large chest tube; admission |
| The class poll (slide 80): most associated = tracheal deviation away from the collapsed lung (not hypertension, bradycardia or neck subcutaneous emphysema). The slide 58 picture orders it “immediate decompression then chest tube”; slide 66 puts the tube first. | |
Tension pushes everything AWAY and DOWN: trachea away, blood pressure down, breath sounds gone, neck veins up. Act before the film.
Away trachea deviated away from the collapsed sideDown hypotension (less venous return, less cardiac output)Gone absent breath sounds on that sideUp distended neck veins
| Finding | Meaning |
|---|---|
| Pleural fluid hematocrit >50% of blood hematocrit | Hemothorax (slide 74 picture) |
| Bloody fluid, hematocrit <50% | Hemorrhagic effusion |
| Chest tube output >200 mL/hr | Thoracotomy (slide 69) |
| Straight air-fluid line, no meniscus | Hemopneumothorax (slide 71) |
| Trauma is the most common cause; the chest tube evacuates and quantifies the bleeding. Retained blood → empyema, fibrothorax, trapped lung. Current guidelines differ: thoracotomy at 1500 mL on insertion or 200 mL/hr for 2–4 hours. | |
Half and Two Hundred: fluid hematocrit over half the blood’s = hemothorax; over 200 mL an hour out of the tube = open the chest.
Half >50% of the blood hematocrit = hemothorax200 mL/hr from the tube = thoracotomy
Where it breaks: The flat, meniscus-free line of hemopneumothorax is not in the hook.
| Pneumothorax | Pleural effusion | |
|---|---|---|
| Inspection | Tachypnea; decreased excursion on the affected side | Asymmetrical expansion; trachea away if >1000 mL |
| Tactile fremitus | Decreased/absent | Decreased |
| Percussion | Hyperresonance | Dullness over fluid |
| Breath sounds | Diminished/absent on that side | Diminished/absent; bronchial toward the top |
| Also | Tachycardia | Pleural friction rub |
| EFFUSION VOLUMES | ||
| <300 mL | — | No physical exam findings (slide 87) |
| 75 mL / 175 mL | — | Blunts the posterior angle (lateral film) / the lateral angle (frontal film) (slide 90) |
| 10 mL | — | Smallest amount contrast CT may find (slide 93) |
| 50–100 mL | — | Removed by diagnostic thoracentesis (slide 96) |
Air Booms, water Thuds; both muffle the fremitus and the breath sounds. Volumes: 10 on CT, 75 on the side, 175 on the front, 300 to feel it, 1000 to push the trachea.
Boom pneumothorax: hyperresonanceThud effusion: dullnessBoth decreased fremitus and breath sounds75 / 175 posterior angle (lateral) / lateral angle (frontal)300 / 1000 exam findings start / trachea shifts away
| Criterion | Transudate | Exudate |
|---|---|---|
| Pleural fluid protein ÷ serum protein | ≤ 0.5 | > 0.5 |
| Pleural fluid lactate dehydrogenase ÷ serum lactate dehydrogenase | ≤ 0.6 | > 0.6 |
| Pleural fluid lactate dehydrogenase | ≤ 2/3 upper limit of normal serum | > 2/3 upper limit of normal serum |
| Rule | ALL three absent (slide 110) | AT LEAST ONE (slide 101) |
| Mechanism (slide 112) | ↑ hydrostatic or ↓ oncotic pressure (low protein) | ↑ capillary permeability from inflammation (high protein) |
| Causes (slide 112) | Heart failure, cirrhosis, nephrotic syndrome | Infection, malignancy, pulmonary embolism, autoimmune |
| ★ “that makes great test questions.” Pulmonary embolism is exudative on slide 112, transudative on slide 111 and “variable” on slide 83: no question keys its class. | ||
Point Five, Point Six, Two-Thirds: ONE is enough to make it an exudate.
0.5 protein ratio >0.50.6 lactate dehydrogenase ratio >0.62/3 fluid lactate dehydrogenase >2/3 of the serum upper limitOne at least one = exudateNone all absent = transudate
| Appearance | Usually means |
|---|---|
| Clear / straw | Transudative effusion |
| Cloudy | Inflammatory exudative effusion |
| Purulent | Empyema |
| Bloody | Hemothorax or malignancy |
| Milky white | Chylothorax (elevated triglycerides, slide 105) |
| Black | Rare fungal infection |
| Appearance alone is not diagnostic; interpret it with the laboratory results and the clinical picture. | |
Clear is Congestion, Cloudy is Inflamed, Pus is Empyema, Blood is Trauma or Tumor, Milk is the thoracic duct.
Clear transudateCloudy inflammatory exudatePus empyemaBlood hemothorax or malignancyMilk chylothorax
Where it breaks: Black (rare fungal infection) has no word in the hook.
| Transudate (low protein) | Exudate (high protein) | |
|---|---|---|
| Most common | Congestive heart failure (>90%) (slide 111) | Pneumonia; malignancy second (breast, lung, lymphoma 75%) (slide 102); tuberculosis the leading cause worldwide (slide 103) |
| Others | Cirrhosis with ascites; nephrotic syndrome; peritoneal dialysis | Viral, bacterial, fungal, parasitic infection; connective tissue disease; asbestosis; pancreatic disease; chylothorax |
| Slide 83 picture: always | Heart failure, hepatic hydrothorax, nephrotic syndrome, atelectasis, hypoalbuminemia | Parapneumonic effusion, empyema, connective tissue disease, hemothorax, asbestos |
| Slide 83 picture, variable: malignancy, pulmonary embolism, sarcoidosis, chylothorax, pancreatitis, thyroid disease. Pulmonary embolism moves between columns (transudate slide 111, exudate slide 112, variable slide 83); chylothorax and pancreatic disease are exudates on slide 103 but variable on slide 83. “Malignancy and CHF [congestive heart failure] are gonna be your frequent flyers.” | ||
Pumps, filters, pipes: a failing Pump (heart) or Filter (liver, kidney), or fluid leaking through the diaphragm (cirrhosis, dialysis), makes a transudate; Leaky pipes (pneumonia, cancer, tuberculosis) make an exudate.
Pump congestive heart failure, >90% of transudatesFilter cirrhosis, nephrotic syndromeDiaphragm cirrhosis, peritoneal dialysisLeaky pipes exudate: pneumonia most common, malignancy second, tuberculosis worldwide
Where it breaks: Malignancy, pulmonary embolism, chylothorax and pancreatic disease change columns between slides.
| Measurement (slide 6) | Arterial blood | Venous blood |
|---|---|---|
| pH (range) | 7.40 (7.35–7.45) | 7.36 (7.31–7.41) |
| Partial pressure of oxygen, mm Hg (decreases with age) | 80–100 | 30–50 |
| Partial pressure of carbon dioxide, mm Hg | 36–44 | 40–52 |
| Oxygen saturation, % (decreases with age) | >95 | 60–85 |
| Bicarbonate, mEq/L | 22–26 | 22–28 |
| Base difference (deficit/excess) | −2 to +2 | −2 to +2 |
| Slide 3: acidemia = pH <7.35, alkalemia = pH >7.45. Slide 10 gives carbon dioxide as 35–45, slide 6 as 36–44: both are on the slides, so no question should turn on the ends of the range. | ||
Arterial gas = 7.40, 40, 24, each give or take a little: pH ± 0.05, carbon dioxide ± 4 (or 5), bicarbonate ± 2.
7.40 ± 0.05 pH 7.35–7.4540 ± 4 (or 5) carbon dioxide 36–44 (slide 6) or 35–45 (slide 10) mm Hg24 ± 2 bicarbonate 22–26 mEq/L± 2 base difference, arterial and venous alike
Where it breaks: The venous column does not follow the pattern: lower pH, higher carbon dioxide, far lower oxygen.
| Item | Slide wording |
|---|---|
| Formula (slides 7, 26) | Anion gap = sodium − (bicarbonate + chloride) |
| Normal (slide 7) | 6–12 mmol/L (average about 10) |
| Increased gap (slide 7) | Increased unmeasured anions: anionic proteins (albumin), ketoacids, phosphate, lactate; decreased unmeasured cations: calcium, magnesium, potassium; increased albumin |
| Decreased gap (slide 7) | Increased unmeasured cations; addition of abnormal cations: lithium; decreased albumin; hyperviscosity and severe hyperlipidemia can affect the sodium and chloride estimates |
| Albumin range (slide 8) | 3.5–5.5 g/dL |
| Correction (slide 8) | The gap must be corrected if albumin is abnormal: add 2.5 mmol/L for each 1 g/dL of serum albumin below 4.5 g/dL |
| Worked example (slide 8) | Albumin 2.5 g/dL (2 below 4.5), uncorrected gap 15 → add 2.5 × 2 = 5 → corrected gap 20 |
| Rule (slide 26) | The gap can be abnormal even when sodium, chloride and bicarbonate are normal |
| Gap cut-offs on different slides: normal 6–12 (slides 7, 47); “Think: anion gap >12” for the raised-gap causes (slide 44); “>20 mEq/L suggests a primary metabolic disorder” (slide 26); decreased <6 (slide 48). | |
Sodium minus the two big anions, about 10 (6 to 12). Albumin hides acid: for every gram it falls below 4.5, give the gap back 2.5.
Na − (HCO3 + Cl) sodium minus (bicarbonate + chloride)6–12, about 10 normal gap4.5 the albumin you correct to2.5 added per 1 g/dL below 4.515 + 5 = 20 the slide 8 example
Where it breaks: The correction only adds for a LOW albumin; the slide gives no subtraction for a high one.
| Disorder | pH | Primary change |
|---|---|---|
| Respiratory acidosis | ↓ (acidemia, <7.35) | ↑ carbon dioxide |
| Respiratory alkalosis | ↑ (alkalemia, >7.45) | ↓ carbon dioxide |
| Metabolic acidosis | ↓ (acidemia) | ↓ bicarbonate |
| Metabolic alkalosis | ↑ (alkalemia) | ↑ bicarbonate |
| Slide 10 normals: pH 7.35–7.45, carbon dioxide 35–45, bicarbonate 22–26. Slide 58 (picture): a normal pH = no abnormality or a mixed acid-base disorder. Slide 59 (picture) splits at bicarbonate 24 mM and carbon dioxide 40 mm Hg; respiratory disorders get renal compensation, metabolic disorders get respiratory compensation. | ||
ROME: Respiratory Opposite, Metabolic Equal.
Respiratory Opposite carbon dioxide moves opposite to pH (up in acidosis, down in alkalosis)Metabolic Equal bicarbonate moves the same way as pH (down in acidosis, up in alkalosis)
Where it breaks: ROME is an outside memory aid, not on the slide; it names only the primary change, not the compensation.
| Disorder (slide 24) | Primary defect | Compensatory response | Magnitude of compensation |
|---|---|---|---|
| Respiratory acidosis, acute | ↑ carbon dioxide | ↑ bicarbonate | ↑ bicarbonate 1 mEq/L per 10 mm Hg ↑ carbon dioxide |
| Respiratory acidosis, chronic | ↑ carbon dioxide | ↑ bicarbonate | ↑ bicarbonate 3.5 mEq/L per 10 mm Hg ↑ carbon dioxide |
| Respiratory alkalosis, acute | ↓ carbon dioxide | ↓ bicarbonate | ↓ bicarbonate 2 mEq/L per 10 mm Hg ↓ carbon dioxide |
| Respiratory alkalosis, chronic | ↓ carbon dioxide | ↓ bicarbonate | ↓ bicarbonate 5 mEq/L per 10 mm Hg ↓ carbon dioxide |
| Metabolic acidosis | ↓ bicarbonate | ↓ carbon dioxide | ↓ carbon dioxide 1.3 mm Hg per 1 mEq/L ↓ bicarbonate |
| Metabolic alkalosis | ↑ bicarbonate | ↑ carbon dioxide | ↑ carbon dioxide 0.75 mm Hg per 1 mEq/L ↑ bicarbonate |
| Slide 23: respiratory cause → renal compensation (bicarbonate retained or excreted); renal cause → respiratory compensation (carbon dioxide retained or excreted). Compensation will NOT fully correct the pH; the underlying condition MUST be corrected. Inadequate or excessive compensation points to a mixed disorder; there cannot be more than one primary respiratory disorder. Slide 34: chronic = after 24–48 hours of sustained raised carbon dioxide. | |||
| For metabolic acidosis the course works the expected carbon dioxide with the Winter formula (slide 49), not the 1.3 ratio; questions give the ratios when they are needed. | |||
Respiratory: acid 1 then 3.5, alkali 2 then 5 (per 10, acute then chronic). Metabolic: acid 1.3, alkali 0.75 (per 1).
1 acute respiratory acidosis3.5 chronic respiratory acidosis2 acute respiratory alkalosis5 chronic respiratory alkalosis1.3 metabolic acidosis (carbon dioxide falls)0.75 metabolic alkalosis (carbon dioxide rises)
Where it breaks: Respiratory ratios are bicarbonate per 10 mm Hg of carbon dioxide; metabolic ratios flip to carbon dioxide per 1 mEq/L of bicarbonate. Chronic is always the bigger number: the kidneys need 24–48 hours.
| Measured carbon dioxide | Reading (slide 49) |
|---|---|
| Expected carbon dioxide = 1.5 × bicarbonate + 8, ± 2 | Winter formula; for anion gap and non-anion gap acidosis alike |
| = expected (within the ± 2) | Metabolic acidosis only |
| > expected | Concurrent respiratory acidosis |
| < expected | Concurrent respiratory alkalosis |
| Slide 28 keys: metabolic acidosis + respiratory alkalosis = high or normal gap acidosis, carbon dioxide below predicted; metabolic acidosis + respiratory acidosis = carbon dioxide above predicted. The slide prints “+ 8 + 2” with the plus-or-minus underline. | |
“One and a half, plus eight, give or take two.” Lungs breathing too little leave carbon dioxide HIGH (add respiratory acidosis); too much leaves it LOW (add respiratory alkalosis).
1.5 × bicarbonate + 8 ± 2 expected carbon dioxideIn range metabolic acidosis onlyHigh + respiratory acidosisLow + respiratory alkalosis
Where it breaks: Only for a primary metabolic acidosis: the slide gives no Winter-type formula for metabolic alkalosis (use the 0.75 ratio).
| Comparison | Reading (slide 50) |
|---|---|
| Change in anion gap = calculated gap − normal gap (10 is an accepted value) | Slides 27, 50 |
| Change in bicarbonate = the fall from normal bicarbonate (25 is an accepted value) | Slides 27, 50 |
| Change in gap = change in bicarbonate | Metabolic acidosis only |
| Change in gap > change in bicarbonate | Concurrent metabolic alkalosis; only detectable if the gap is high |
| Change in gap < change in bicarbonate | Check the change in chloride! |
| Change in bicarbonate = change in gap + change in chloride | Concurrent increased-gap AND normal-gap metabolic acidosis |
| Slide 27: the change in gap should equal the change in bicarbonate; differences indicate mixed disorders; then examine the patient again: do the clinical findings support the acid-base analysis? The slides write the bicarbonate change as “lab result − normal”; use the size of the fall from 25. | |
Every point the gap rises should cost one point of bicarbonate. Bicarbonate fell too LITTLE = something added base (alkalosis). Bicarbonate fell too MUCH = chloride took the rest (a second, normal-gap acidosis).
Gap = bicarbonate pure raised-gap acidosisGap > bicarbonate + metabolic alkalosis (needs a high gap)Gap < bicarbonate check chlorideGap + chloride = bicarbonate + normal-gap acidosis10 / 25 accepted normal gap / bicarbonate
Where it breaks: Only meaningful with a raised gap; a normal-gap acidosis alone has no gap change to compare.
| Mixed disorder | Key | Slide example (cause) |
|---|---|---|
| METABOLIC + RESPIRATORY (slides 28–29) | ||
| Metabolic acidosis — respiratory alkalosis | High or normal gap metabolic acidosis; carbon dioxide below predicted | Bicarbonate 14, gap 20, carbon dioxide 24, pH 7.39 (lactic acidosis, sepsis in the intensive care unit) |
| Metabolic acidosis — respiratory acidosis | High or normal gap metabolic acidosis; carbon dioxide above predicted | Bicarbonate 18, gap 20, carbon dioxide 38, pH 7.30 (severe pneumonia, pulmonary edema) |
| Metabolic alkalosis — respiratory alkalosis | Carbon dioxide does not increase as predicted; pH higher than expected | Bicarbonate 33, gap 16, carbon dioxide 38, pH 7.55 (liver disease and diuretics) |
| Metabolic alkalosis — respiratory acidosis | Carbon dioxide higher than predicted; pH normal | Bicarbonate 42, gap 10, carbon dioxide 67, pH 7.42 (chronic obstructive pulmonary disease on diuretics) |
| METABOLIC + METABOLIC (slide 30) | ||
| Metabolic acidosis — metabolic alkalosis | Only detectable with high-gap acidosis; change in gap much greater than change in bicarbonate | Bicarbonate 25, gap 20, carbon dioxide 40, pH 7.42 (uremia with vomiting) |
| Metabolic acidosis — metabolic acidosis | Mixed high-gap + normal-gap acidosis; change in bicarbonate accounted for by the combined change in gap and chloride | Bicarbonate 10, gap 15, carbon dioxide 25, pH 7.20 (diarrhea and lactic acidosis, toluene toxicity, treatment of diabetic ketoacidosis) |
| Each example also gives sodium 140 (135 in the last) and potassium 4.0 (3.5 or 3.0 in the last three). Three of the six have a normal pH (7.39, 7.42, 7.42): a normal pH does not rule out a mixed disorder (slide 58). Only one respiratory disorder at a time (slide 23). | ||
Six marriages, never two lungs: the lung partner shows up in the carbon dioxide (below or above predicted); the second kidney partner shows up in the gap-versus-bicarbonate math.
Low or too-low carbon dioxide + respiratory alkalosis (sepsis, liver disease)High carbon dioxide + respiratory acidosis (pneumonia, chronic obstructive pulmonary disease on diuretics)Gap >> bicarbonate acidosis + alkalosis (uremia with vomiting)Gap + chloride high-gap + normal-gap acidosis (diarrhea and lactic acidosis)
Where it breaks: Respiratory acidosis + respiratory alkalosis is not a pair: only one respiratory disorder at a time.
| Letter | Cause (slide 44) |
|---|---|
| M | Methanol, metformin |
| U | Uremia |
| D | Diabetic / alcoholic / starvation ketoacidosis |
| P | Paraldehyde, propylene glycol |
| I | Isoniazid, iron |
| L | Lactic acidosis |
| E | Ethylene glycol |
| S | Salicylates, starvation |
| Also | Renal failure, rhabdomyolysis |
| Slide 44: think anion gap >12; think metabolic anions, renal failure, toxins. The slide spells “Ethelyne glycol”. | |
MUDPILES (the slide’s own aid).
M methanol, metforminU uremiaD diabetic, alcoholic, starvation ketoacidosisP paraldehyde, propylene glycolI isoniazid, ironL lactic acidosisE ethylene glycolS salicylates, starvation
Where it breaks: Renal failure and rhabdomyolysis sit outside the letters (“Also”). Four letters carry two causes (M, P, I, S).
| Group | Slide items |
|---|---|
| Ketoacidosis | Diabetic; alcoholic; starvation |
| Lactic acidosis | Poor tissue perfusion; tissue necrosis; severe anemia; trauma |
| Renal failure | Chronic; acute |
| Toxins | Salicylates; alcohols (methanol, ethylene glycol); 5-oxoproline acidosis from acetaminophen toxicity |
The Usual Suspects are KiLleR Toxins.
K Ketoacidosis: diabetic, alcoholic, starvationL Lactic acidosis: perfusion, necrosis, anemia, traumaR Renal failure: acute or chronicToxins salicylates, alcohols, acetaminophen (5-oxoproline)
Where it breaks: Acetaminophen is the toxin not in MUDPILES.
| Letter | Cause (slide 46) |
|---|---|
| U | Ureteral diversion |
| S | Saline infusion |
| E | Exogenous acid |
| D | Diarrhea |
| C | Carbonic anhydrase inhibitors |
| A | Adrenal insufficiency |
| R | Renal tubular acidosis |
| Also | Chlorine gas exposure; hyperalimentation (total parenteral nutrition) |
| SLIDE 47: NORMAL GAP (6–12) BY MECHANISM | |
| Loss of bicarbonate | Diarrhea; recovery from diabetic ketoacidosis; pancreatic fluid loss, ileostomy (unadapted); carbonic anhydrase inhibitors |
| Chloride retention | Renal tubular acidosis; ileal loop bladder |
| Administration of hydrochloric acid equivalent or ammonium chloride | Administration of hydrochloric acid equivalent or ammonium chloride; arginine and lysine in parenteral nutrition |
| Slide 46: think gastrointestinal bicarbonate loss, renal tubular acidosis. Diabetic ketoacidosis itself is a raised-gap cause (slides 44–45); its recovery is normal-gap (slide 47). | |
USEDCAR (the slide’s own aid); sort it as Leak, Keep, Add: bicarbonate Leaks out, chloride is Kept, acid is Added.
U ureteral diversionS saline infusionE exogenous acidD diarrheaC carbonic anhydrase inhibitorsA adrenal insufficiencyR renal tubular acidosis
Where it breaks: Chlorine gas and hyperalimentation are extras outside the letters.
| Cause (slide 48: gap <6) | Detail |
|---|---|
| Hypoalbuminemia | Decreased unmeasured anion; the gap must be corrected |
| Plasma cell dyscrasias | Monoclonal protein (cationic paraprotein accompanied by chloride and bicarbonate) |
| Bromide intoxication | |
| Slide 7 adds lithium (an abnormal cation) and hyperviscosity or severe hyperlipidemia (sodium and chloride estimates). | |
Low gap = Little albumin, Lots of paraprotein, Bromide.
Little albumin hypoalbuminemia: correct the gapLots of paraprotein plasma cell dyscrasiasBromide bromide intoxication
Where it breaks: Lithium (slide 7) is not in the hook.
| Type | Urine chloride (slide 51) | Causes (slide 53) |
|---|---|---|
| Saline-responsive | Lower: <25 mEq/L | Volume contraction; diuretics (sodium reabsorption, hydrogen ion secretion); vomiting or gastric suction (loss of gastric hydrochloric acid); ingestion of alkaline drugs (sodium bicarbonate); post-hypercapnia |
| Saline-unresponsive, normotensive | Higher: >40 mEq/L | Severe potassium depletion; hypoparathyroidism and hypercalcemia |
| Saline-unresponsive, hypertensive | Higher: >40 mEq/L | Primary aldosteronism; exogenous alkali; mineralocorticoids; licorice |
| Slide 51: metabolic alkalosis is not as common as metabolic acidosis. Slide 54: if the cause is unclear, measure urinary chloride to narrow the differential. Slide 53 puts alkaline drugs under saline-responsive and exogenous alkali under hypertensive saline-unresponsive: never decided by group. | ||
Under 25, saline revives; over 40, take the blood pressure. Hypertensive = MEAL.
<25 saline-responsive>40, normal pressure potassium depletion; hypoparathyroidism and hypercalcemiaM MineralocorticoidsE Exogenous alkaliA Aldosteronism (primary)L Licorice
Where it breaks: Urine chloride between 25 and 40 is not assigned on the slide.
| Value | Slide wording |
|---|---|
| pH <6.7 or >7.6 (slide 12) | Unsustainable: may cause cardiac hypocontractility/irritability, seizures, cerebral edema, metabolic disturbances; may warrant therapy to normalize the pH along with treatment of the cause |
| Carbon dioxide >80 mm Hg and oxygen <40 mm Hg (slide 36) | Acute/severe impairment of carbon dioxide excretion with life-threatening hypoxia: adequate ventilation (emergency airway, mechanical ventilator), clear secretions, oxygen |
| Respiratory alkalosis, pH <7.50 (slide 40) | Mild: treatment usually not required |
6.7 and 7.6 are mirror digits; 80 in, 40 out is a ventilator; under 7.50 is just breathing fast.
6.7 / 7.6 unsustainable pH80 / 40 carbon dioxide above 80 with oxygen below 40: ventilate7.50 mild respiratory alkalosis: usually no treatment
| Term | What you need to know |
|---|---|
| ★ CAN vs CANNOT | Capitals on the slide: sleep = unconsciousness from which a person CAN be aroused; coma = one from which a person CANNOT. |
| ★ Two basic types | Her focus: REM vs non-REM, the “two basic overviews”; the separate N1–N3 details and the sleep-wake paragraph are background (know it is positive feedback). |
| ★ Exhausted → little REM | Very sleepy: REM episodes short or absent; they lengthen as the person is rested. |
| ★ Non-REM | Deep, restful; increased parasympathetic tone; dreams happen but are not remembered (no memory consolidation). |
| Stages | For this course: three non-REM stages (N1–N3), she said in class; some slides show four. |
| Term | What you need to know |
|---|---|
| Non-REM (slow-wave) | Deep, extremely restful; increased parasympathetic tone; blood pressure, heart rate, breathing and metabolic rate 10–30% lower; dreams less vivid and often not remembered (not consolidated). Stages N1, N2 (the majority), N3. |
| REM | Not restful; vivid dreams with muscle activity; muscle tone very depressed (atonia except eyes and diaphragm); heart rate and breathing irregular; brain metabolism up to 20% higher; harder to arouse than non-REM, yet spontaneous morning waking happens in REM. |
| Paradoxical / desynchronized | REM’s EEG looks like wakefulness (paradoxical sleep); neurons fire without synchrony (desynchronized sleep). |
| Very sleepy | REM episodes are short or absent; they lengthen as the person becomes rested. |
| Term | What you need to know |
|---|---|
| Sleep restriction | Over a few days: worse cognitive and physical performance, productivity and health. |
| Two effect types | On the nervous system and on other body systems; the exact functions remain a mystery. |
| Functions | Neural maturation; learning and memory; targeted erasure of synapses; cognition; clearing metabolic waste of the awake brain; conserving metabolic energy. |
| Waking up | Sleep centers off → mesencephalic and upper pontile reticular activating nuclei released → cortex excited → positive feedback keeps wakefulness going. |
| Falling asleep | Hours later the activating neurons fatigue, the feedback loop fades and sleep-promoting centers take over. No definitive explanation exists. |
| Term | What you need to know |
|---|---|
| ★ AT NIGHT | Capitals on the slide: untreated obstructive sleep apnea carries 3–6 times the risk of sudden cardiac death AT NIGHT. |
| ★ ** ASV | Asterisks on the slide: adaptive servo-ventilation is not used for all patients, especially in heart failure with reduced ejection fraction. |
| ★ Gold standards | Split-night and all-night polysomnogram (obstructive apnea); polysomnography with continuous carbon dioxide monitoring (obesity hypoventilation). |
| ★ Diagnosis, simply | “As simple as possible”: 5 or more obstructive events per hour plus a symptom, or 15 or more. Home kit = obstructive apnea only; not with cardiopulmonary or neuromuscular disease, and not for central apnea. |
| ★ Education | “Patient education is like the most important thing”: CPAP is the most effective but disliked, so counsel. Severe obstructive apnea: oral appliance not effective, use CPAP. |
| ★ Central apnea risk factors | “I really want everyone to understand”: heart failure, stroke, opioids, hypoxia, high altitude, CPAP use. Treat the cause first, then CPAP, then ASV (not with poor left ventricular function). |
| ★ OHS | Diagnosis of exclusion; male gender is not a risk factor; first line weight loss + BiPAP or CPAP (“first line, first line, first line”). |
| ★ Women | After menopause more than before: “the age will help you a lot.” |
| Term | What you need to know |
|---|---|
| Who and why | Most common sleep-disordered breathing; rises with age; men > women; post- > premenopausal; upper airway narrowing by soft tissue or structure. |
| Risk factors | Obesity; big tongue, small or set-back jaw; neck 17 in (men) / 16 in (women); big tonsils; age; male; family history; alcohol or sedatives; hypothyroidism. |
| History | Daytime sleepiness, unrefreshing sleep, witnessed apnea, snorting or gasping, loud habitual snoring, morning headache, nocturia, poorly controlled hypertension, poor memory, low libido, night sweats. |
| Exam | Obesity, macroglossia, micrognathia, retrognathia, large neck, enlarged tonsils, crowded posterior oropharynx. |
| Tests | Thyroid-stimulating hormone if hypothyroid; split-night (2 hours, then CPAP titration) or all-night polysomnogram (mild to moderate at baseline); titration study if the diagnosis is known. |
| Differential | Central sleep apnea, nocturnal dyspnea (heart failure), swallowing disorder, panic attacks, nocturnal asthma, reflux, nocturnal seizures, narcolepsy, periodic limb movements. |
| Term | What you need to know |
|---|---|
| Most effective | Continuous positive airway pressure (CPAP). |
| Other devices | Autotitrating PAP only without significant comorbidities; positional therapy if supine-only; oral appliance not for severe disease or no teeth; nasal expiratory resistance device. |
| Drugs | Modafinil or armodafinil: headache, anxiety, dizziness, nausea, hypersensitivity, many interactions; caution with cardiovascular, hepatic, psychiatric disease; lower doses in the elderly. Nasal steroids for allergic congestion. |
| Surgery | Radiofrequency ablation (mild to moderate, CPAP-intolerant); palatal implants (mild); maxillomandibular advancement; tracheostomy is a cure; bariatric surgery may help. |
| Lifestyle and referral | Diet and exercise for weight loss; avoid alcohol and sedatives; refer to a sleep physician; counseling. |
| Older adults | Lower mortality (they compensate) but drowsiness and nocturia, which improve with CPAP. |
| Term | What you need to know |
|---|---|
| Heart | Arrhythmias, bradycardia, sympathetic tone up, blood pressure variability; ischemic heart disease; heart failure mortality; aortic aneurysm and dissection. |
| Lungs | Group 3 pulmonary hypertension (especially with obesity hypoventilation or daytime hypoxemia). |
| Metabolic | Insulin resistance, type 2 diabetes and its complications; glucose and triglycerides up; worse cardiovascular risk in metabolic syndrome; fatty liver 2–3 times; gout. |
| Other | Stroke; reflux 75–100%; C-reactive protein, cortisol, amyloid up; growth hormone, prolactin down; cytokines up (improve with CPAP). |
| Term | What you need to know |
|---|---|
| Mechanism | Brainstem stops signaling: high carbon dioxide sensitivity → hyperventilation alternating with apnea; no effort (obstructive: effort against a collapsed airway). |
| Risk factors | Heart failure (Cheyne-Stokes; circulation delay to the carotid chemoreceptors), stroke, opioids, hypoxia, high altitude, CPAP use. |
| Presentation | Insomnia, awakenings, nocturnal dyspnea, nonrestorative sleep, sleepiness; less snoring. |
| Diagnosis | Polysomnography (home not sufficient): repetitive apneas without thoracic-abdominal excursion. |
| Treatment | Treat the cause (optimize heart failure therapy, reduce opioids, descend) → CPAP → adaptive servo-ventilation if CPAP fails, not in reduced ejection fraction. |
| Term | What you need to know |
|---|---|
| Definition | Awake alveolar hypoventilation (raised awake carbon dioxide) in an obese person, not explained by anything else (Pickwickian syndrome). |
| Risk factors | Central obesity, reduced lung function, weak inspiratory muscles, severe obstructive sleep apnea; male sex is NOT a risk factor; 50s and 60s. |
| Presentation | 90% have obstructive apnea symptoms (70% severe); 10% sleep hypoventilation (older women, fewer witnessed apneas); many present late with hypercapnic respiratory failure or right heart failure. |
| Complications | Pulmonary hypertension, right-sided heart failure, sleepiness, hypertension, heart failure, insulin resistance; refer to a sleep specialist. |
| Prognosis | High mortality; cardiovascular disease is the leading cause of death; more hospital and intensive care use; worse with significant awake hypoxemia at diagnosis. |
| Term | What you need to know |
|---|---|
| ★ History is the clue | “A person showing up at a place with a thing”: occupation, hobbies, exposure, timing. The presentations look alike (exertional dyspnea, dry cough, crackles); the history separates them. |
| ★ Pay attention | The laboratory clue table (sedimentation rate and angiotensin-converting enzyme = sarcoid, c-ANCA = granulomatosis with polyangiitis, anti-basement membrane = Goodpasture, antinuclear antibody = collagen vascular). |
| ★ Board pointers | Lupus pernio + dry cough → sarcoid; ferruginous bodies → asbestos; milky lavage → silicosis; hypersensitivity pneumonitis: find the agent, avoid the agent; idiopathic pulmonary fibrosis is the most common. |
| Not tested | Don’t memorize the cause/drug charts; rare subtypes (“desquamative interstitial pneumonia on a test? No”); few Churg-Strauss / Wegener questions; sarcoid immunology slide. |
| Most time | Acute respiratory distress syndrome (11 of 66 minutes): a feared complication of sepsis, trauma, aspiration and more; the pictures carry AI typos (“Chuck” = shock). |
| Term | What you need to know |
|---|---|
| What it is | 200+ disorders of scarring and/or inflammation of the parenchyma (alveoli, ducts, respiratory bronchioles); not malignant, not infectious; stiff, restrictive lungs → shortness of breath. |
| How | Inflammatory cells in alveolar walls → alveolitis → fibroblasts → collagen = fibrosis (permanent). |
| Two groups | Inflammation and fibrosis vs granulomatous; each known or unknown cause. Known: inorganic and organic dusts, fumes, gases. Unknown: sarcoidosis, idiopathic pulmonary fibrosis, connective tissue disease. |
| Drug causes | Methotrexate, amiodarone, nitrofurantoin, bleomycin, chemotherapy, radiation (and the long slide 9 list). |
| Symptoms | Progressive exertional dyspnea or persistent nonproductive cough; hemoptysis, wheeze, chest pain, tachypnea, anorexia; later dyspnea at rest. |
| Exam | Small lung volumes, bibasilar dry rales (inspiratory crackles), clubbing, right heart failure late; may be normal early. |
| Term | What you need to know |
|---|---|
| Subtypes | Idiopathic pulmonary fibrosis (most common), desquamative, nonspecific, cryptogenic organizing, respiratory bronchiolitis-associated, lymphoid, acute interstitial. |
| Smoking | 67–75% of idiopathic and familial fibrosis patients have smoked; smoking is the cause in the majority; cessation is critical. |
| Picture | Insidious dry cough, exertional dyspnea, fatigue; clubbing, bibasilar inspiratory crackles, reduced chest expansion. |
| Tests | Restrictive pattern; CT diffuse patchy fibrosis with pleural-based honeycombing; lower-field markings; biopsy may be needed (lavage, transbronchial, surgical). |
| Treatment | Controversial: nothing improves survival vs no treatment; steroids only for cryptogenic organizing, lymphoid and nonspecific subtypes. |
| Term | What you need to know |
|---|---|
| Connective tissue | Lupus, rheumatoid arthritis, ankylosing spondylitis, systemic sclerosis, Sjögren, polymyositis-dermatomyositis, scleroderma. Methotrexate treats them and also causes interstitial lung disease. |
| Hemorrhage syndromes | Goodpasture (anti-basement membrane), idiopathic pulmonary hemosiderosis, isolated pulmonary capillaritis. |
| Granulomatous | Sarcoidosis; granulomatosis with polyangiitis (c-ANCA); Churg-Strauss; hypersensitivity pneumonitis. |
| Term | What you need to know |
|---|---|
| Who | Multi-organ, noncaseating granulomas, lungs and lymphatics most; North American Black and Northern European white people; women; third and fourth decades. |
| Picture | Cough, insidious dyspnea, chest discomfort, malaise, fever, weight loss, nontender lymphadenopathy; erythema nodosum (painful rashes, lower legs), parotid enlargement, lupus pernio (painful skin sores, face), hepatosplenomegaly. |
| Tests | Film: symmetric bilateral hilar and right paratracheal adenopathy; angiotensin-converting enzyme up in 40–80%, hypercalcemia (5%), hypercalciuria, eosinophilia, high sedimentation rate; biopsy confirms (transbronchial or fine-needle node). |
| Treatment | Corticosteroids (90% respond) for the listed indications; methotrexate, azathioprine, infliximab if intolerant or refractory. |
| Follow-up | Yearly: exam, pulmonary function, chest film, electrocardiogram, chemistry, eye exam. |
| Term | What you need to know |
|---|---|
| What | Non-atopic, non-asthmatic; inhaled organic dust: moldy hay (farmer’s lung), bird excreta and feathers (bird fancier’s), cheese maker’s lung, moldy sugarcane, infested grain. |
| Picture | Malaise, chills, fever, cough, dyspnea, nausea hours after exposure; may mimic paroxysmal nocturnal dyspnea (worse after work at home); crackles, tachypnea, tachycardia, cyanosis. |
| Tests | Serum antibodies to the agent = definitive; white count up with left shift; hypoxia; restrictive; small nodules sparing apices and bases; biopsy if subacute or chronic; noncaseating granulomas. |
| Treatment | Identify and avoid the agent; steroids if severe; supportive; transplant. Reversible if caught early. |
| Term | What you need to know |
|---|---|
| Causes | Direct: aspiration, diffuse pneumonia, contusion, toxic gas, near-drowning, emboli. Systemic: sepsis (about a third of cases), pancreatitis, shock, trauma, overdoses, transfusions, amiodarone, nitrofurantoin. |
| Picture | Dyspnea 12–48 hours after the insult; hypoxemia refractory to oxygen; tachypnea, retractions, crackles; multiorgan failure. |
| Imaging | Bilateral infiltrates becoming confluent; air bronchograms (about 80%); normal heart size, few effusions; echocardiogram excludes cardiogenic edema (cardiomegaly, batwing opacities). |
| Management | Treat the cause; low tidal volume; positive end-expiratory pressure for arterial oxygen above 60; early prone positioning (moderate to severe); conservative fluids; transfuse at 7 g/dL; steroids within 14 days (conditional); avoid oscillatory ventilation and routine pulmonary artery catheters; neuromuscular blockade controversial; ECMO (extracorporeal membrane oxygenation) salvage. |
| Prognosis | Mortality about 30% (20% trauma to 80% end-stage liver disease); lung function recovers over 6–12 months; residual diffusion deficits, weakness, fatigue. |
| Term | What you need to know |
|---|---|
| ★ The one thing | “If you walk away with nothing else”: about 25% of proven pulmonary embolisms have no dyspnea. Don’t rely on shortness of breath. |
| ★ Board questions | S1Q3T3 = right ventricular strain (highly specific, low sensitivity); Westermark, Hampton’s hump, Palla: “great for board questions,” rarely seen. |
| ★ Fair game | Wells and PERC: “easy math.” Wells first; ≤4 unlikely → PERC (every item negative) → D-dimer; >4 → straight to CT. |
| ★ Know the middle | Embolism submassive = normal pressure + right ventricular strain or raised troponin/BNP (“what you’re gonna get on the PANCE”). Pulmonary hypertension: right ventricular failure signs = automatically high risk. |
| ★ You should know | Phosphodiesterase-5 inhibitors (sildenafil, tadalafil: “your AFILs”); the rest by class (“PROST in the name”). |
| ★ Cor pulmonale | COPD (chronic obstructive pulmonary disease) is the absolute leading cause; alveolar hypoxia is the most important driver; septal flattening = D-shaped left ventricle. |
| ★ The standards | Right heart catheterization confirms pulmonary hypertension; CT pulmonary angiography for embolism (ventilation/perfusion [V/Q] scan if not); echo in embolism is “for stratification,” not diagnosis; CTEPH (chronic thromboembolic pulmonary hypertension) is treated surgically. |
| Not tested | Slide 20 charts; wedge detail (slide 24); the slide 28 intensive-care rule; slide 44 (“don’t go crazy”); whole flowcharts; off-slide asides (sinus tachycardia, drug names). |
| Term | What you need to know |
|---|---|
| Definition | Right ventricular enlargement, hypertrophy or dilation caused exclusively by a primary lung or pulmonary vascular disorder; raised mean pulmonary artery pressure with a normal wedge. Left heart failure (Group 2) is not cor pulmonale. |
| Causes | COPD (>50% of patients), interstitial lung disease, sleep-disordered breathing; acute embolism, pulmonary arterial hypertension (Group 1), CTEPH (Group 4). |
| Mechanism | Global alveolar hypoxia + hypercapnia (“Blue Bloater”) → diffuse vasoconstriction → resistance ↑ → afterload ↑; vascular bed loss; polycythemia raises viscosity. |
| Acute crash | Septum bows into the left ventricle → output plummets → shock; distended neck veins, tricuspid murmur, tachycardia, pallor. |
| Chronic exam | Right ventricular heave, loud P2, tricuspid murmur; tender hepatomegaly, ascites, dependent pitting edema. |
| Tests | EKG: peaked P (right atrium), tall R in V1, right axis deviation (chronic); abnormal in 70% of acute embolism. Echo: systolic septal flattening = D-shape, pulmonary artery systolic pressure. Film: flat diaphragms, big central arteries; fields may look clear. |
| Treat | Treat the lung disease; oxygen is a drug (Group 3); bronchodilators, infection control; lysis + anticoagulation in acute embolism. Careful diuresis: the right ventricle needs preload; watch for hypokalemia. |
| Term | What you need to know |
|---|---|
| Axiom | The most common cause of right ventricular failure overall is left ventricular failure. |
| Pathway | Hypertrophy → dilation and failure → septal bowing into the left ventricle → exertional syncope despite normal left ventricular contractility. |
| Exam | Large a or v waves; right ventricular heave; accentuated P2; right-sided S3; hepatojugular reflux >1 cm; edema to hips/sacrum; cool extremities. S3 = “floppy,” S4 = “stiff” (his). |
| Tests | Echo = most useful initial test; V/Q (ventilation/perfusion) = essential to exclude CTEPH (chronic thromboembolic pulmonary hypertension) (mismatch → thromboendarterectomy); right heart catheterization confirms. |
| Foundations | Careful diuresis; PaO2 (arterial oxygen pressure) >60 mmHg (sleep, exertion); avoid strict bedrest, supervised aerobic rehabilitation; annual influenza and pneumococcal vaccines. |
| End stage | Early palliative care and advance directives (sudden death may come first); 6% survival at 90 days after CPR; lung transplantation = only definitive option. |
| Term | What you need to know |
|---|---|
| Starling | Outward hydrostatic pressure (the engine of cardiogenic edema) beats inward oncotic pressure, or the membrane shatters. |
| Bedside | Pink frothy sputum (late), bilateral rales/crackles and wheeze, S3, dyspnea, diaphoresis, tripoding. |
| Tests | BNP (B-type natriuretic peptide): substantial rise = cardiogenic; transthoracic echo: structure, ejection fraction, valves; catheter when the cause is uncertain (wedge >18–20 = cardiogenic). |
| Film | Batwing (perihilar edema), peribronchial cuffing, Kerley B (interlobular septa), bilateral effusions; flash edema: butterfly pattern, vascular blurring. |
| Flash edema | Triggers: acute MI, ischemia, severe hypertension; nonadherence, salt, rapid arrhythmias. Upright with legs dangling; IV furosemide; IV nitrates; continue beta-blockers unless shock; hold outpatient therapy in acute kidney injury; cautious morphine. |
| Chronic | Quadruple therapy (angiotensin receptor-neprilysin inhibitor [ARNI], beta-blocker, mineralocorticoid receptor antagonist, sodium-glucose cotransporter-2 [SGLT-2] inhibitor) = greatest mortality reduction in reduced ejection fraction. |
| Term | What you need to know |
|---|---|
| Continuum | Deep venous thrombosis and embolism are one disease: asymptomatic to collapse and death. |
| Presentation | Isolated dyspnea; pleuritic pain + hemoptysis (infarction, friction rub); collapse (obstructive shock = massive). 25% no dyspnea. |
| D-dimer | High sensitivity, low specificity; negative ELISA (enzyme-linked immunosorbent assay) excludes; outpatients only (inpatient false positives). |
| Echo | Massive embolism → septum bows into the left ventricle → output crashes. Poor sensitivity (~50%), very high specificity for right ventricular strain: risk stratification, not diagnosis. |
| Treatment | Anticoagulate all; lyse the unstable; thrombectomy/embolectomy when lysis is contraindicated or a clot is in transit; screen for CTEPH (chronic thromboembolic pulmonary hypertension) at 3 months. |
| Term | What you need to know |
|---|---|
| Adult (reduced ejection fraction) | Ischemia-driven pump loss; higher reserve; aggressive diuresis generally well tolerated. |
| Elderly (preserved ejection fraction) | Age-related stiffening, high end-diastolic pressure; extreme preload sensitivity, narrow margin; gentle, precise diuresis (over = hypotension, under = recurrent flooding). |
| Age and PERC (Pulmonary Embolism Rule-out Criteria) | PERC needs age <50: an older patient cannot pass it. |
| Referral | Stage D heart failure → transplant, assist device or hospice; refractory pulmonary hypertension → lung transplant; abnormal V/Q (ventilation/perfusion) at 3 months → expert center (thromboendarterectomy). |
| Term | What you need to know |
|---|---|
| ★ His exam list | Slide 49 “Things to Know”: screening, benign vs worrying nodule, staging and its treatment, central vs peripheral, recognize squamous and small cell, radiotherapy, paraneoplastic signs. “Big picture, guys.” |
| ★ Board pointer (3x) | “Small and squamous are central”; adenocarcinoma and large cell peripheral. |
| ★ Magic number 6 | Over 6 mm = suspicious, especially upper lobe or hilar and spiculated (“spiky”; “you don’t usually see a lot of benign stuff that’s described as spiculated”). |
| ★ Test-question pointer | Large cell metastasizes to the small intestine and bowel: “unique to a thing makes a great test question.” |
| ★ Squamous | Strongest smoking link, central from a bronchus, cavitation, cough/wheeze/hemoptysis like a COPD (chronic obstructive pulmonary disease) flare that never settles; sputum can catch it; hypercalcemia. |
| ★ Small cell | Does better with chemotherapy and radiation (best in limited stage); prophylactic cranial irradiation; SIADH: confusion and seizures in the emergency department → “oh, that’s lung cancer.” |
| Not to memorize | Fleischner tables (reports print them), probability tables, staging charts in detail, node stations, genes, marker-to-drug choices, small cell follow-up schedule. Primary care: screen, figure out risk, refer. |
| Most time | Epidemiology and spread 7.5 min; incidental nodules and symptoms 7.1; staging 5.25 (of about 55 minutes taught). |
| Term | What you need to know |
|---|---|
| Found how | Incidentally on a chest X-ray or CT done for another reason; size first: under 6 mm not concerning unless high risk; a solitary nodule on chest X-ray = coin lesion. |
| Usually | Benign: granuloma (inflammatory) or hamartoma (connective tissue growth); high-risk patients are worked up to exclude malignancy. |
| Workup | Chest X-ray “not a good tool”; CT with contrast of chest and upper abdomen, then biopsy (bronchoscopy, transthoracic, thoracoscopy by location; can be CT guided); PET; genetic testing. |
| Labs | Complete blood count with differential, metabolic panel with calcium, alkaline phosphatase, pulmonary function tests; sputum cytology (not sensitive). |
| PET | Radioactive sugar (fludeoxyglucose): high uptake suggests malignancy; low or normal uptake is a good sign; inflammation can also take it up. |
| Benign CT | Smooth nodule with fat and calcification = hamartoma; central calcification = healed granuloma; next to the minor fissure = scar or lymphoid tissue. |
| Term | What you need to know |
|---|---|
| Deaths | >30% of cancer deaths in men (highest of all cancers in men), >25% in women; five-year survival 17–18%. |
| Smoking | 85–90% of cases (second-hand smoke 20%); packs per day × years compound it (5x, 10x, 20x). |
| Other risks | Radiation and radon, air pollution, chemical toxins, tuberculosis or HIV (human immunodeficiency virus) infection, genetics, diet, alcohol. |
| Age | Most over 50; about 4% under 40 (keep it on the differential). |
| Types | Small cell (oat cell, 15–20%) and non-small cell: adenocarcinoma (most common), squamous (20–30%), large cell (9–10%); rare: carcinoid, bronchial gland, sarcomatoid, Pancoast. |
| Spread | Oncogenes on, tumor suppressors off; most masses in or near the hilum, some peripheral (hard to find); to regional nodes, then liver, brain, bone; hyperplasia → dysplasia → in situ → invasive → metastases. |
| Term | What you need to know |
|---|---|
| Work up if | Persistent cough, hemoptysis, dysphagia, wheeze or shortness of breath, weight loss, fever or fatigue, bone or chest pain, endocrine disorders. |
| Why deadly | No symptoms until advanced or metastatic; in COPD it can pass for an exacerbation. |
| Brain | Headache, vision change, nausea, vomiting, syncope, seizures; papilledema (raised intracranial pressure); cranial nerve signs (midbrain/pons). |
| Liver | Dull right upper quadrant ache, firm hepatomegaly, poor appetite, jaundice, hepatic failure. |
| Bone | Pain; fractures without falls (a cough can fracture the spine); spinal cord compression. |
| Adrenal | Adrenal insufficiency (slide heading “Kidneys”): fatigue, weight loss, dizziness, hypotension, low sodium with high potassium (not SIADH). |
| Term | What you need to know |
|---|---|
| Adenocarcinoma | Most common; periphery, mid-lung; peripheral scars; smoking not always; from type II pneumocytes (atypical adenomatous hyperplasia, in situ, lepidic, invasive); mucicarmine stain = mucin; spiculated peripheral nodule; 2/3 present advanced. |
| Large cell | Diagnosis of exclusion; anaplastic, pleomorphic, cells 3x larger; periphery; necrosis and hemorrhage; large cavitated peripheral mass; mets to small intestine and bowel; no standard treatment; mucicarmine negative. |
| Squamous cell | 2nd most common (20–30%); strongest smoking link; central, from a bronchus; obstruction → cough, wheeze, hemoptysis, atelectasis, pneumonia; local invasion → dysphagia, voice change; sputum cytology; hypercalcemia; cavitated spiculated lesion. |
| Non-small cell treatment | Resection (wedge, segment, lobectomy, pneumonectomy) if the patient can tolerate it; chemotherapy/radiation as adjuncts or stage 4; markers (TP53, EGFR, KRAS, ALK) let the oncologist tailor therapy; checkpoint inhibitors (“-mab”, PD-1 pathway) keep T cells on. |
| Term | What you need to know |
|---|---|
| Picture | Oat cell; central, infiltrates the mucosa; insidious: >70% metastatic (liver, bone, brain) before detection; high cavitation once large; chromosome 3 short-arm lesion. |
| Paraneoplastic | Neuroendocrine (APUD, amine precursor uptake and decarboxylation) cells secreting polypeptide hormones → SIADH. |
| Histology | Fragile, crushed at biopsy; small cells, no nucleoli, high nuclear-to-cytoplasm ratio. |
| Treatment | Responds better to chemotherapy and radiation than non-small cell; radiation best in limited stage; prophylactic cranial irradiation; adjunct immunotherapy (nivolumab, atezolizumab). |
| Radiation effects | Acute: skin erythema and hyperpigmentation (ulceration risk), inflammation, hair loss, little nausea. Chronic: pulmonary fibrosis, coronary and valve disease, cardiomyopathy, lymphedema (think axillary), neuropathy. |
| Term | What you need to know |
|---|---|
| What | Hormonal or cytokine effects of tumor tissue (primary or metastasis): endocrine, neurological, dermatological, hematological. |
| SIADH (small cell) | Excess antidiuretic hormone (vasopressin) → water retention → low sodium, low osmolality → confusion, seizures, ataxia; no edema (insidious). |
| Hypercalcemia | Particularly squamous cell; calcium is in the lab workup. |
| Lambert-Eaton | Autoimmune attack on calcium channels at nerve endings → less acetylcholine → progressive leg weakness; neuromuscular junction; rare (3000 a year). |
| Carcinoid syndrome | Mainly from a bronchial carcinoid; serotonin: flushing, apparent cyanosis, pulmonic and tricuspid valve thickening, wheeze, hepatomegaly, diarrhea, cramps, retroperitoneal and pelvic fibrosis. |
| Term | What you need to know |
|---|---|
| Older adults | Screen 55–80 (30 pack-years, smoking or quit within 15 years); most cancers over 50; unfit for lobectomy → segmentectomy; unfit for surgery → radiotherapy or ablation. |
| Brain radiation | Prophylactic cranial irradiation not recommended with poor performance status or impaired neurocognitive function. |
| Referral | High probability or moderate/intense PET uptake → pulmonologist, thoracic surgeon, interventional radiologist or oncologist; primary care screens, judges risk and refers. |
| Education | Smoking cessation (risk compounds with dose); screening false positives; symptoms come late. |
| Term | What you need to know |
|---|---|
| ★ Light’s criteria | “that makes great test questions”: protein ratio >0.5, lactate dehydrogenase ratio >0.6, fluid lactate dehydrogenase >2/3 of the serum upper limit; one is enough for an exudate. |
| ★ Tension | Recognize it at the bedside and act (“I don’t have to prove it”): hypotension, trachea away, neck veins distended, absent breath sounds. The poll answer: tracheal deviation away from the collapsed lung. |
| ★ Needle site | “For test purposes for now, that would be the right answer”: 2nd intercostal space, over the 3rd rib, midclavicular line (typical site, not only site). |
| ★ Board trap | Tall, thin 22-year-old with Marfan syndrome = secondary spontaneous pneumothorax. |
| ★ Numbers he likes | 3 cm apex to cupola (“a nice, easy number”); the stability list (“don’t overthink it”). “Don’t confuse gold standard [CT] with best initial test [upright chest film].” |
| ★ Education | “this may be a question you get”: recurrence approaches 50% within 3 years; stop smoking; thoracoscopic surgery with pleurodesis is the best prevention. |
| ★ Effusions | “Malignancy and CHF [congestive heart failure] are gonna be your frequent flyers”; heart failure is about 90% of transudates. |
| Lighter touch | Causes of pleurisy; procedure details and chest tube sizes (“know what the toolbox looks like”); the slide 97 laboratory thresholds (“Don’t go crazy about this”); flow charts. |
| Most time | Pneumothorax took about 60% of the lecture (procedures, treatment and education, imaging and size, types, traumatic and tension). |
| Term | What you need to know |
|---|---|
| Pressure | Intrapleural pressure is always negative (about −4 mm Hg: 756 vs 760); the chest wall pulls out, the lung recoils in, and the suction keeps the lung inflated. |
| Pleurisy | Inflammation of the parietal pleura; a symptom, not a diagnosis. Causes: idiopathic, trauma, infection, lupus or rheumatoid arthritis, pneumothorax, pulmonary embolism, malignancy, drugs (methotrexate, amiodarone, hydralazine). |
| Picture | Well-localized sharp pain worse with breathing, coughing, movement, sneezing; central diaphragm → ipsilateral shoulder or neck pain. |
| Exam | Tachypnea, limited expansion; pleural friction rub (grating, both phases) that disappears when the breath is held (a pericardial rub does not). |
| Rule out first | Myocardial infarction, pericarditis, aortic dissection, pneumonia, pneumothorax, pulmonary embolism (“big scary things”); then rib or vertebral fracture, costochondritis, zoster. |
| Treat | The underlying condition + nonsteroidal anti-inflammatory drugs. |
| Term | What you need to know |
|---|---|
| Cause | Rupture of apical blebs (<1 cm, in the visceral pleura) or bullae (>1 cm). |
| History | Often at rest; acute dyspnea + ipsilateral pleuritic chest pain (severe, stabbing, worse with deep breaths); may be asymptomatic if small; cough less common. |
| Exam | Tachypnea, tachycardia, decreased excursion, decreased/absent fremitus, hyperresonance, diminished/absent breath and voice sounds on that side. |
| Secondary | Same picture but worse (less reserve); infection adds cough, fever, chills. |
| Differential | Myocardial infarction, pulmonary embolism, aortic dissection, pericarditis, pleurisy, muscle strain, costochondritis. |
| Term | What you need to know |
|---|---|
| Upright chest film | Initial test: the visceral pleural line with no markings beyond it. |
| Supine film | Deep sulcus sign: a dark, deep costophrenic angle from air collecting laterally. |
| Ultrasound | Bedside, for the unstable patient: absent lung sliding; does not size it. |
| CT | Gold standard for presence, size and location; finds blebs and bullae; impractical when time is critical. |
| Tension on a film | Mediastinal shift, diaphragm depression: “You should never ever see this before recognizing it.” |
| Term | What you need to know |
|---|---|
| Goals | Evacuate the space; close the leak; prevent recurrence. |
| Catheter aspiration | Large-gauge needle, catheter, 3-way stopcock, syringe; 2nd space midclavicular; over 2 liters out → consider a persistent air leak; film afterward. |
| Heimlich valve | One-way flutter valve on a chest tube; small, portable, lets the patient walk. |
| Chest tube | Drains air or fluid; pneumothorax or effusion; 4th or 5th space midaxillary. |
| Pleurodesis | Inflames the pleura so the layers stick (no space for air or fluid): mechanical (surgical abrasion) or chemical (talc or drugs via chest tube or thoracoscope). Most common use: malignant effusion. |
| Surgery | Thoracoscopic surgery has largely replaced open thoracotomy; thoracotomy stays for complicated cases. |
| Term | What you need to know |
|---|---|
| Recurrence | Approaches 50% within 3 years (slide 59); one-third of primary cases within 1–2 years, >60% after a second episode, >75% on the same side (slide 60). |
| Lifestyle | Stop smoking (up to 100-fold risk); delay air travel 7–14 days after a film confirms resolution; avoid scuba diving; hold positive pressure during an active leak. |
| Refer | Surgical evaluation for an air leak >4 days; pilots and divers early; genetics for a family history. |
| Term | What you need to know |
|---|---|
| Traumatic | Gunshot, stab, blunt trauma with rib fractures, cardiopulmonary resuscitation, mechanical ventilation: ask “Have you had any trauma?” |
| Closed vs open | Closed: no wound, air from the lung. Open: chest-wall wound lets air in on inhalation (sucking chest wound). |
| Tension | One-way valve; hypotension, trachea away, neck veins up, breath sounds gone; clinical diagnosis. |
| Act | Chest tube now; if none, needle at the 2nd space midclavicular, then a chest tube. “This needle buys moments.” Never aspirate. |
| Term | What you need to know |
|---|---|
| Cause | Trauma most common (heart, great vessels, lung, intercostal or internal thoracic arteries); neoplasms. |
| Define | Fluid hematocrit >50% of the blood’s; strictly exudative. Hemopneumothorax: straight line, no meniscus. |
| Treat | Chest tube to evacuate and quantify; >200 mL/hr → thoracotomy. |
| Risk | Retained blood → empyema, fibrothorax, trapped lung. An effusion that grows on anticoagulation needs a tap. |
| Term | What you need to know |
|---|---|
| Cause | Alveoli rupture next to the mediastinum (high pressure), esophageal perforation, or air tracking from neck or abdomen; after violent coughing, vomiting, inhaled drugs (Valsalva). |
| Picture | Pleuritic chest or neck pain, sore throat, dyspnea, cough. |
| Exam | Subcutaneous emphysema in the neck; Hamman crunch: substernal crackling with each heartbeat (“snap, crackle, and pop”). |
| Treat | Airway; treat the cause; conservative (oxygen, rest, analgesics); severe → emergent cardiothoracic surgery. |
| Term | What you need to know |
|---|---|
| Mechanisms | Altered permeability (inflammation, malignancy, pulmonary embolism); ↓ oncotic pressure (nephrotic syndrome, cirrhosis); ↑ hydrostatic pressure (heart failure); blocked lymphatics (malignancy, trauma); peritoneal fluid across the diaphragm (cirrhosis, dialysis). |
| Who | >1.5 million a year in the United States; heart failure the leading cause; malignant effusions can come years after a cancer diagnosis; asbestos exposure. |
| Symptoms | None if small; dyspnea, dry cough, pleuritic pain referred to the shoulder or upper abdomen. |
| Clues | Edema, orthopnea, paroxysmal nocturnal dyspnea → heart failure; fever, purulent sputum → pneumonia; hemoptysis → malignancy; night sweats, weight loss → tuberculosis. |
| Term | What you need to know |
|---|---|
| Imaging | Upright film (75 mL posterior, 175 mL lateral angle); decubitus film (effusion side down) now replaced by ultrasound, which also guides the tap; contrast CT finds 10 mL and associated disease. |
| Loculation | Fluid trapped in compartments by adhesions between the pleurae (empyema). |
| Thoracentesis | Diagnostic (50–100 mL) for a new effusion with no clinical cause; therapeutic relieves symptoms. |
| Send for | Protein, lactate dehydrogenase, white count with differential, Gram stain, cytology (malignancy), culture; then Light’s criteria. |
| Term | What you need to know |
|---|---|
| Chylothorax | Thoracic duct disruption (trauma, thoracic surgery most common; mediastinal tumors) → milky fluid, high triglycerides. Treat: chest tube or intermittent taps without over-draining (nutrition), octreotide, cut long-chain triglycerides. |
| Empyema | Pus in the pleural space; pneumonia with a parapneumonic effusion is the usual precursor; suspect it when pneumonia does not resolve. Treat: drainage + antibiotics promptly. |
| Term | What you need to know |
|---|---|
| Transudates | Congestive heart failure >90%; cirrhosis with ascites, nephrotic syndrome, peritoneal dialysis. |
| Treat | Treat the underlying disorder (diuretics first for heart failure); therapeutic thoracentesis; chest tube. |
| Recurrent malignant | Pleurodesis = palliative (lung, breast, ovarian); indwelling tunneled catheter placed as an outpatient and drained at home for short prognoses or a non-expandable lung. |
| Term | What you need to know |
|---|---|
| What | Viral myalgia of the striated intercostal muscles, usually coxsackie B virus; after an upper respiratory or gastrointestinal infection; summer. |
| Picture | Fever with paroxysms of knife-like pain lasting 15–30 minutes: pleuritic in adults, abdominal in children; splinting, tender muscles. |
| Tests | Elevated creatine kinase; chest film usually normal (rules out other causes). |
| Treat | Supportive: NSAIDs (nonsteroidal anti-inflammatory drugs) and heat. Slide 118: resolves in 2–4 days, may recur; the slide 119 picture says 4–6 days (not keyed). |
| Term | What you need to know |
|---|---|
| ★ Compensation | “Tattoo on the inside of your eyeballs”: compensation will never fully correct the pH in a simple disorder. |
| ★ Normal pH | A normal pH with abnormal values does not mean there is no mixed problem (three of the six slide examples have a normal pH). |
| ★ One lung | Only one respiratory disorder at a time; several metabolic disorders can coexist. |
| ★ Big gap | A big anion gap is always metabolic; respiratory disorders do not cause large gaps (slide 26: >20 suggests a primary metabolic disorder). |
| ★ Winter formula | Expected carbon dioxide = 1.5 × bicarbonate + 8, ± 2. Above = concurrent respiratory acidosis; below = concurrent respiratory alkalosis. |
| ★ Gap vs bicarbonate | Change in gap (from 10) vs fall in bicarbonate (from 25): equal = simple; gap bigger = + metabolic alkalosis (only with a high gap); bicarbonate bigger = check chloride; = gap + chloride = high-gap + normal-gap acidosis. |
| ★ Albumin | Add 2.5 for every 1 g/dL below 4.5; hypoalbuminemia lowers the gap, so the gap must be corrected (slides 8, 48). |
| ★ Acute vs chronic | Respiratory acidosis: bicarbonate up 1 (acute) vs 3.5 (chronic) per 10 mm Hg of carbon dioxide. |
| ★ Treat the cause | “Golden rule”: find and treat the underlying condition; always circle back to the patient (slide 27). Stop respiratory depressants (narcotics, benzodiazepines); careful oxygen in chronic retainers; do not overcorrect an alkalosis. |
| ★ Calculate | She expects the calculations (gap, corrected gap, Winter, compensation), not the nomogram (slide 25); lab values come with reference ranges and the albumin. |
| Lighter touch | Renal physiology detail (slides 20–21); plasma cell dyscrasias and bromide; licorice; the less common normal-gap causes. |
| Term | What you need to know |
|---|---|
| Definitions | Simple (primary) disorder = one primary disturbance + its compensation; mixed = more than one primary disturbance at once (slide 4). |
| Potassium | Alkalosis: hydrogen ions out of cells, potassium in → hypokalemia. Acidosis: hydrogen ions in, potassium out → hyperkalemia (slide 5). |
| Oxygen | Alkalosis: hemoglobin holds oxygen tighter → less delivered to tissues. Acidosis: lower affinity → more delivered (slide 5). |
| Acids | Volatile (carbonic acid, from fats and carbohydrates) → lungs. Nonvolatile (proteins, ingested sulfates and phosphates) → kidneys (slide 13). |
| Buffers | Renal/respiratory = most important overall; carbon dioxide adjusts quickly, bicarbonate slowly (hours to days). Intracellular buffers (proteins, phosphate, hemoglobin) do 60–70%; bone (slides 14, 19). |
| Kidney | Cannot excrete free hydrogen ions: buffered by ammonium and titratable acids (major one: hydrogen phosphate); urinary bicarbonate should be 0; urine pH can fall to 4.0 (slides 20–21). |
| Lungs | Brain stem senses cerebral pH; more carbon dioxide → faster breathing. Hyperventilation ↓ carbon dioxide; hypoventilation ↑ it (slides 18, 22). |
| Term | What you need to know |
|---|---|
| 1 | Arterial blood gas and electrolytes together; compare the two bicarbonates to verify accuracy (slide 56). |
| 2 | pH: acidosis or alkalosis? Carbon dioxide and bicarbonate: respiratory or metabolic? |
| 3 | Calculate the anion gap; correct for hypoalbuminemia. |
| 4 | Estimate the compensation: appropriate? Excess or inadequate = mixed disorder (slides 26, 57). |
| 5 | Which mixed disorders? pH, carbon dioxide, bicarbonate; change in gap, bicarbonate and chloride. |
| 6 | Does it match the clinical picture? If there is a second disorder, find and treat both causes (slides 56–57, 63). |
| Term | What you need to know |
|---|---|
| What | ↑ carbon dioxide from decreased alveolar ventilation, NEVER increased production (slide 31). |
| Causes (slide 32) | Central nervous system depression (sedatives, central event); neuromuscular and musculoskeletal disorders (myopathies, neuropathies, kyphoscoliosis, Guillain-Barré syndrome, myasthenia gravis, botulism, polymyositis); hemothorax, pneumothorax; flail chest; acute airway obstruction (upper airway, laryngospasm, bronchospasm); severe pneumonia or pulmonary edema; ventilator dysfunction; obesity-hypoventilation syndrome; pleural effusion; chronic obstructive pulmonary disease, acute respiratory distress syndrome. (Slide 32 also lists pulmonary embolism; slide 39 lists lung disease under respiratory alkalosis, so its direction is not keyed.) |
| Acute or chronic | Bicarbonate up 1 per 10 mm Hg (acute) vs 3.5 after 24–48 hours (chronic). Slide 35: carbon dioxide 80 → compare the measured bicarbonate with each expected value. |
| Treat | Underlying condition; stop respiratory depressants (narcotics, benzodiazepines). Carbon dioxide >80 with oxygen <40: ventilate (airway, ventilator), clear secretions, oxygen (slide 36). |
| Chronic | Same, with careful oxygen: a rapidly falling carbon dioxide can trigger alkalosis complications (arrhythmias, reduced cerebral perfusion, seizures) (slide 37). |
| Term | What you need to know |
|---|---|
| What | pH >7.45 with ↓ carbon dioxide (slide 38). |
| Causes (slide 39) | Anxiety; hypoxia; high altitude (physiologic); lung disease with or without hypoxia; decreased lung compliance (interstitial fibrosis); central nervous system disease; catastrophic central event (intracerebral hemorrhage). |
| Treat (slide 40) | Mild (pH <7.50): usually none. Treat pain, anxiety, fever, infection or salicylate overdose; mindful breathing. On a ventilator: decrease minute volume (fewer breaths or smaller tidal volume). |
| Term | What you need to know |
|---|---|
| What | Excess acid to buffer or net loss of bicarbonate; compensation = lower carbon dioxide by breathing more (slide 41). |
| Symptoms | Mostly the underlying disorder; compensatory hyperventilation; Kussmaul breathing in severe acidosis: deep, regular, sighing breaths (slide 42). |
| Raised gap | MUDPILES + renal failure, rhabdomyolysis; Big 4: ketoacidosis, lactic acidosis, renal failure, toxins (slides 44–45). |
| Normal gap | USEDCAR; slide 46: “Think: gastrointestinal bicarbonate loss, renal tubular acidosis”. |
| Respiratory partner | Winter formula: above = + respiratory acidosis; below = + respiratory alkalosis (slide 49). |
| Metabolic partner | Change in gap vs change in bicarbonate (slide 50). |
| Term | What you need to know |
|---|---|
| What | pH >7.45, hydrogen ions ↓, bicarbonate ↑; less common than metabolic acidosis (slide 51). |
| Symptoms | Mostly the underlying disorder; hypokalemia → weakness, hyporeflexia; rarely tetany and neuromuscular irritability (slide 52). |
| Urine chloride | <25 = saline-responsive; >40 = saline-unresponsive (then normotensive or hypertensive). |
| Treat (slide 54) | Underlying condition; unclear cause → urine chloride; stop diuretics, nasogastric suction, corticosteroids; replace fluid and potassium; don’t overcorrect! |
| Steroids (slide 55) | Lower the dose or switch to less mineralocorticoid activity (consider prednisone or methylprednisolone vs cortisone or hydrocortisone). Consider excess alkali, glucose after starvation, high-dose penicillin, profound potassium depletion, endogenous mineralocorticoid excess. |